Common Variable Immunodeficiency: Evidence-Based Clinical Summary

On this page

Quick Reference

RxDrug of choiceImmunoglobulin replacement therapy (IVIG 400-600 mg/kg q3-4wk or SCIG 100-200 mg/kg weekly) titrated to individual trough.

AltAlternativesAntimicrobial prophylaxis (TMP-SMX DS daily or azithromycin 250 mg TIW); for non-infectious complications: prednisone ≥0.3 mg/kg/day, rituximab 150-375 mg/m², abatacept (CTLA-4 insufficiency), sirolimus (LRBA deficiency), omalizumab (CSU), PD-1 inhibitors (malignancy).

⊘AvoidLive vaccines; IgA-containing IVIG in patients with anti-IgA antibodies; non-dihydropyridine CCBs (diltiazem, verapamil) in CVID with cardiac involvement.

DxTest of choiceSerum immunoglobulins (IgG, IgA, IgM, IgE) plus vaccine response testing (pneumococcal polysaccharide + protein antigens) plus B-cell immunophenotyping (switched memory B cells, CD21low B cells).

ScKey scoreEUROclass classification (smB <2% = high risk; CD21low >10% = lymphoproliferation) and clinical phenotype (infection-only vs complicated CVID).

→When to referRefer to immunology at diagnosis; consider specialized center for complicated CVID (non-infectious complications, monogenic defect, refractory disease, need for HSCT or targeted biologic).

CVID is the most common primary immunodeficiency in adults, driven by humoral and T-cell defects. Early immunoglobulin replacement reduces infections, but non-infectious complications (autoimmune cytopenias, lymphoproliferation, GLILD, malignancy) determine prognosis and require targeted immunosuppression. Monogenic causes guide therapy, and systematic surveillance improves outcomes.

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency in adults, characterized by low serum immunoglobulins (IgG and IgA and/or IgM) and impaired specific antibody responses. The disease manifests with recurrent sinopulmonary infections, autoimmune cytopenias, lymphoproliferation, enteropathy, and increased malignancy risk, complications that now dominate morbidity and mortality. Diagnostic delays of 5-8 years are common. Early immunoglobulin replacement therapy reduces infection frequency and improves survival; effective management requires parallel strategies for infectious prophylaxis and targeted immunosuppression for non-infectious complications. This overview synthesizes the current paradigm for evaluation and management.

Overview and Recommendations

Background

•CVID is the most common symptomatic primary immunodeficiency in adults, with an estimated prevalence of 1 in 500 to 1 in 500,000. It is defined by low serum IgG and low IgA (with or without low IgM) and defective specific antibody production, leading to recurrent infections and immune dysregulation that spans B- and T-cell compartments.
•The classic presentation involves recurrent sinopulmonary infections (pneumonia as first manifestation in 32% of patients), but non-infectious complications, autoimmune cytopenias (ITP, AIHA, Evans syndrome), lymphoproliferation (splenomegaly, lymphadenopathy), enteropathy, granulomatous-lymphocytic interstitial lung disease (GLILD), and malignancy, now drive most morbidity. The presence of even one non-infectious complication confers an 11-fold increase in mortality compared with infection-only disease.
•Pathophysiology centers on a fundamental B-cell maturational defect (reduced class-switched memory B cells) compounded by T-cell dysregulation: follicular helper T-cell expansion, regulatory T-cell deficiency, and chronic innate immune activation driven by microbial translocation. IgA deficiency with impaired anti-LPS antibodies permits endotoxemia, which triggers a BTK-dependent proinflammatory cytokine cascade (TNF-α, IL-6, IFN-γ, CXCL9, CXCL10) in genetically susceptible individuals.
•Monogenic causes are identified in 20-30% of patients, most commonly heterozygous loss-of-function variants in (4% of Europeans), haploinsufficiency, deficiency, and defects in , , , and . Identification of a specific genetic defect can guide targeted therapy (e.g., abatacept for CTLA-4 insufficiency, sirolimus for LRBA deficiency) and consideration of hematopoietic stem cell transplantation.
•Diagnostic criteria per ESID/ICON require onset after age 2 years, low IgG and low IgA (and/or low IgM), impaired vaccine responses to pneumococcal polysaccharide and protein antigens, and exclusion of secondary causes of hypogammaglobulinemia. Patients are clinically stratified into infection-only (CVIDio) and complicated CVID (CVIDc), the latter encompassing autoimmune, lymphoproliferative, enteropathic, and malignant phenotypes, to guide prognosis and surveillance intensity.

Evaluation

•Suspect CVID in any adult with recurrent sinopulmonary infections (≥2 pneumonias in 1 year, chronic sinusitis, otitis media), especially when accompanied by unexplained autoimmune cytopenia, splenomegaly, lymphadenopathy, chronic diarrhea, or bronchiectasis.
•Ask about age at first serious infection, frequency of antibiotic courses, history of pneumonia, bronchiectasis, autoimmune disease (ITP, AIHA, Evans syndrome), family history of immunodeficiency, and prior immunoglobulin measurements. Diagnostic delay averages 5-8 years, so maintain a low threshold.
•Examine for signs of chronic lung disease (crackles, clubbing), lymphadenopathy, splenomegaly, mucocutaneous candidiasis, and skin findings (vitiligo in 8.5%, eczema in 22.4%, purpura from thrombocytopenia).
•Order initial laboratory workup: complete blood count with differential, serum immunoglobulins (IgG, IgA, IgM, IgE), and serum protein electrophoresis with calculated globulin (CG <22 g/L has 80% sensitivity, 87% specificity for hypogammaglobulinemia). Low IgG and low IgA are required for diagnosis.
•Evaluate specific antibody responses by measuring pre- and 4-week post-vaccination titers to pneumococcal polysaccharide (Pneumovax) and protein antigens (tetanus, diphtheria). Failure to achieve a ≥2-fold rise or protective levels in <70% of serotypes defines the defect. If the patient is already on IVIG, use ELISPOT assay for antibody-secreting cells instead of serology.
•Perform B-cell immunophenotyping by flow cytometry: quantify switched memory B cells (CD27+IgD-), marked reduction (<2% of B cells) is a hallmark of CVID and predicts non-infectious complications. Expansion of CD21low B cells (>5% of B cells) correlates with GLILD and splenomegaly.
•Assess T-cell subsets: low naive CD4+ T cells (<20% of total CD4+) defines late-onset combined immunodeficiency (LOCID), which independently predicts splenomegaly, lymphadenopathy, interstitial lung disease, lymphoma, and shortened survival.
•Consider serum B-cell maturation antigen (sBCMA) as a novel biomarker: <15 ng/mL has 97% positive predictive value for CVID or X-linked agammaglobulinemia; ≥25 ng/mL has 88% negative predictive value.
•Genetic testing (targeted gene panel or whole exome) is indicated for patients with non-infectious complications dominating the phenotype, family history of immunodeficiency, or severe/atypical infections. Identification of a monogenic cause (NFKB1, CTLA4, LRBA, etc.) can direct targeted therapy and cascade screening of relatives.
•In patients with atopic symptoms but negative skin prick testing or serum specific IgE, consider bronchial challenge to confirm allergic asthma, as standard allergy testing is often falsely negative in CVID (only 9.7% have atopy by skin test despite suggestive histories).
•Rule out secondary causes of hypogammaglobulinemia: medications (rituximab, anticonvulsants, sulfasalazine), protein-losing enteropathy, nephrotic syndrome, lymphoproliferative diseases (CLL, thymoma/Good syndrome), and chronic infections (HIV, EBV, CMV).
•Perform baseline screening for established complications: high-resolution chest CT (HRCT) to assess for bronchiectasis and GLILD, pulmonary function tests including FVC and DLCO, and upper endoscopy with standardized biopsies to screen for atrophic gastritis and intestinal metaplasia (found in 34% of CVID patients) if gastrointestinal symptoms are present.
•Refer to an immunologist for confirmation and initiation of immunoglobulin replacement therapy; coordinate a multidisciplinary approach including pulmonology, gastroenterology, and hematology for complicated cases.

Management

•Initiate immunoglobulin replacement therapy (IgRT) as soon as the diagnosis is confirmed. Start 400-600 mg/kg every 3-4 weeks or 100-200 mg/kg weekly; titrate the dose to maintain a trough IgG >700-800 mg/dL, though the ideal level should be individualized based on breakthrough infection frequency.
•SCIG is increasingly preferred for its flexibility, fewer systemic adverse effects, suitability for home administration, and improved quality of life. IVIG remains appropriate for patients who prefer center-based therapy or have adherence concerns.
•For breakthrough sinopulmonary infections despite adequate trough IgG levels, add antimicrobial prophylaxis: one double-strength tablet daily or 250 mg three times weekly. Tailor choice based on sputum culture results when possible.
•Manage GLILD with high-dose corticosteroids: initiate at ≥0.3 mg/kg daily (or equivalent). This regimen improves HRCT scores and forced vital capacity, achieving durable remission in approximately 42% of patients. Low-dose maintenance (<0.3 mg/kg) provides no added benefit, taper to the lowest effective dose over 4-8 weeks.
•For steroid-refractory or relapsing GLILD, use -based therapy. Low-dose rituximab 150 mg/m² weekly may achieve remission with fewer infections; standard-dose rituximab 375 mg/m² every 3 weeks is an alternative but carries a higher risk of opportunistic infections. Combination with azathioprine (dose per protocol) has shown benefit in case series.
•For autoimmune cytopenias (ITP, AIHA, Evans syndrome), first-line treatment is high-dose corticosteroids (e.g., pulse therapy). For refractory cases, consider rituximab, azathioprine, or other steroid-sparing immunosuppressants. Maintain IgG trough >7 g/L to reduce autoimmune thrombocytopenia episodes.
•In monogenic CVID due to haploinsufficiency, administer abatacept (CTLA-4 fusion protein) as targeted therapy. Hematopoietic stem cell transplantation (HSCT) can achieve sustained remission in 72% of CTLA-4 mutation carriers and is also an option for severe deficiency or other monogenic defects with refractory immune dysregulation.
•For LRBA deficiency, (mTOR inhibitor) has demonstrated efficacy in reducing lymphoproliferation and autoimmunity; consider HSCT if disease is severe and progressive.
•For refractory chronic spontaneous urticaria in CVID, can induce complete remission after the first injection and is well tolerated over 12 months.
•For malignancy arising in CVID (e.g., lung adenocarcinoma, lymphoma), (nivolumab, pembrolizumab) have been used successfully, achieving partial response with progression-free survival >15 months. Do not automatically exclude CVID patients from checkpoint inhibitor trials.
•Vaccination: administer inactivated influenza vaccine annually and mRNA vaccine series with boosters as recommended. Humoral responses develop in 52-83% of CVID patients but wane rapidly; T-cell responses are more durable and correlate with protection against severe disease. Live vaccines are contraindicated.
•Monitor for complications systematically: perform annual pulmonary function tests; repeat HRCT every 1-2 years if GLILD is present (consider MRI as radiation-sparing alternative); screen for gastric cancer with baseline upper endoscopy and standardized biopsies at diagnosis, then every 3-5 years (especially in smokers or with H. pylori infection).
•Intubation criteria for acute respiratory failure: FVC <20 mL/kg ideal body weight, PaO2/FiO2 ratio <150 mm Hg on non-rebreather, hypercapnia (PaCO2 >50 mm Hg with pH <7.30), or signs of impending fatigue (accessory muscle use, respiratory rate >35 breaths/min, abdominal paradox).
•Provide standard VTE prophylaxis for hospitalized CVID patients: 40 mg SC daily or 5000 U SC twice daily, unless bleeding risk from severe thrombocytopenia or active bleeding.
•Refer patients with complicated CVID (non-infectious complications, monogenic defect, refractory disease) to specialized immunology/transplant centers for consideration of targeted biologic therapies or HSCT.
•In pregnancy, continue IgRT to maintain trough IgG >500-700 mg/dL; IVIG is safe with no moderate/severe adverse effects. Coordinate multidisciplinary care with maternal-fetal medicine, immunology, and neonatology. Breastfeeding is encouraged as colostrum contains protective antibodies against enteropathogenic E. coli.
•In elderly patients, individualize IgG trough targets to balance infection prevention against volume overload; SCIG may be preferred to avoid hemodynamic stress of IVIG. Monitor for comorbidities (chronic lung disease, diabetes, hypertension) that complicate management.
•Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) as they exacerbate heart failure in patients with cardiac involvement. Avoid IgA-containing immunoglobulin products in patients with known anti-IgA antibodies at risk of anaphylaxis.
•Monitor for iatrogenic complications: corticosteroids increase opportunistic infection risk (2 cases in one series); rituximab may worsen humoral deficiency (compensated by IgRT); checkpoint inhibitors can trigger immune-related adverse events. Adjust immunosuppression in collaboration with the primary immunologist.

Board Review — High Yield

•Low IgG + IgA + impaired vaccine responses, Diagnostic triad for CVID; require onset after age 2 and exclusion of secondary causes.
•EUROclass smB- group, Switched memory B cells <2% of total B cells predicts splenomegaly, granulomatous disease, and lymphoma.
•CVIDc (complicated CVID), Presence of any non-infectious complication (cytopenias, lymphoproliferation, enteropathy) increases mortality 11-fold.
•NFKB1 haploinsufficiency, Most common monogenic cause (4% of Europeans); causes progressive B-cell defect, autoimmunity, and bronchiectasis.
•GLILD, Granulomatous-lymphocytic interstitial lung disease; diagnosed by HRCT + biopsy; treated with high-dose corticosteroids (≥0.3 mg/kg prednisone) ± rituximab.
•IVIG vs SCIG, Both first-line; SCIG has fewer systemic reactions and enables home therapy; target trough IgG >700-800 mg/dL.
•CTLA-4 insufficiency, Responds to abatacept; HSCT can be curative.
•Vaccination in CVID, Humoral responses blunted (52-83% seroconversion to COVID-19 mRNA vaccine, rapid waning); T-cell responses more durable; live vaccines contraindicated.
•Diagnostic delay, Averages 5-8 years; maintain high index of suspicion in adults with recurrent infections + autoimmunity or lymphoproliferation.
•Anaphylaxis risk, FCGR2A gain-of-function variant predisposes to IVIG reactions; switch to SCIG or use IgA-depleted products.

Deep Dive — Evidence Details

Definition, Classification & Immunodeficiency Defect Type

▸CVID is the most common symptomatic primary immunodeficiency in adults, defined by low immunoglobulins and impaired antibody responses.
▸Classification into infection-only (CVIDio) and complicated (CVIDc) phenotypes stratifies prognosis, with CVIDc carrying higher mortality from autoimmune, lymphoproliferative, and malignant complications.
▸Monogenic causes account for 20-30% of cases; NFKB1 loss-of-function is the most common in Europeans, but many patients lack an identifiable genetic variant.

HY High Yield: CVIDc is associated with TH1 polarization, expansion of cytotoxic CD4 TFH cells in lymph nodes, and defective germinal center formation [1,12].

Common Variable Immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency in adults, defined by low serum immunoglobulins (IgG and IgA and/or IgM) and impaired specific antibody responses, leading to recurrent infections, autoimmunity, lymphoproliferation, and increased malignancy risk ^[25]^D5.

Also Called: CVID, common variable immunodeficiency disorder, late-onset hypogammaglobulinemia.

Hypersensitivity Classification: CVID is not classified under the Gell-Coombs hypersensitivity schema. It is a primary immunodeficiency of humoral immunity, driven by defective B-cell differentiation and function. Many patients also exhibit T-cell dysregulation, including TH1 polarization ^[1]^C4 and expansion of a cytotoxic CD4 TFH-cell cluster in lymph nodes ^[12]^B3b, which accounts for the frequent autoimmune and inflammatory complications. Thus, CVID is best framed as a primary immunodeficiency involving both B- and T-cell compartments.

Clinical Phenotypes

The European Society for Immunodeficiencies (ESID) registry provides diagnostic criteria ^[15]^D5. Patients are broadly categorized into infection-only (CVIDio) and complicated CVID (CVIDc) ^[16]^B3b^[32]^C4.

Phenotype	Key Features	Clinical Implication
Infection-only	Recurrent sinopulmonary infections; no autoimmune or lymphoproliferative complications	Lower mortality; better prognosis ^[16]^B3b
Complicated (CVIDc)	Autoimmune cytopenias, lymphoproliferation (splenomegaly, lymphadenopathy), granulomatous disease, enteropathy	Higher mortality from infections and neoplasia; requires targeted immunosuppression ^[16]^B3b
Monogenic subtypes	Pathogenic variants in NFKB1 (most common in Europeans), CTLA4, LRBA, NFKB2, PIK3CD, TACI, BAFFR, CD19, ICOS, TRAF3, RAG2, IRF2BP2	Often autosomal dominant with variable penetrance; may guide therapy (e.g., CTLA-4 fusion protein) ^[6]^C4^[11]^C4^[17]^D5^[26]^C4^[30]^C4^[35]^D5^[37]^C4

Genetic Architecture: A monogenic cause is identified in approximately 20-30% of patients, most commonly heterozygous loss-of-function NFKB1 variants (4% of European CVID) ^[11]^C4^[27]^C4. These defects converge on impaired germinal center formation and B-cell class-switch recombination.

Clinical Significance: CVID carries substantial morbidity. Hepatic complications occur in 10% of hospitalizations and increase in-hospital mortality from 4% to 11% ^[19]^C4. Premature death is driven by infections and malignancy, particularly in CVIDc patients with lymphopenia, thrombocytopenia, or elevated liver enzymes ^[16]^B3b. Early immunoglobulin replacement therapy reduces infection frequency and improves survival ^[34]^C4.

Pearl: CVID is not a hypersensitivity disorder but a primary humoral immunodeficiency with frequent T-cell dysregulation; categorizing patients as infection-only versus complicated CVID (CVIDc) stratifies prognosis - CVIDc carries a higher risk of mortality from autoimmune and lymphoproliferative complications, and should trigger a thorough search for monogenic causes ^[6]^C4^[11]^C4^[16]^B3b.

Pathophysiology & Immune Mechanism

▸CVID is a heterogeneous antibody-deficiency syndrome in which a substantial subgroup develops immune dysregulation and chronic inflammation. [83][238][244]
▸CD21low B-cell expansion, T-bet-high CD21low B cells, IL-10, and altered T-cell/monocyte profiles are linked to complicated CVID. [83][242][245]
▸CD57+ CD8+ T-cell expansion is associated with granuloma or lymphadenopathy and CMV positivity in CVID. [239]
▸Tryptophan–kynurenine metabolism and gut dysbiosis are candidate contributors to inflammatory CVID phenotypes, but association does not establish causality. [9]
▸Monogenic disorders including NFKB1 haploinsufficiency, hypomorphic IL2RG variants, IRF2BP2 deficiency, and STAT3 gain-of-function can produce CVID-like disease. [40][44][47][246]

Dx Diagnostic Essentials: Persistent inflammation, lymphoproliferation, unusual infections, marked T-cell abnormalities, or atypical organ disease should prompt genetic testing or reassessment for a monogenic CVID-like disorder rather than assuming a nonspecific CVID mechanism. [44][240]

! Warning: Findings from CTLA4 deficiency, Good syndrome, CAR-T-associated injury, autoimmune enteropathy, or hereditary angioedema provide differential or mechanistic context and should not be directly attributed to CVID without disease-specific evidence. [54][81][236][237][243]

Core immunobiology

Common variable immunodeficiency (CVID) is a heterogeneous inborn error of immunity in which impaired antibody production coexists, in a clinically important subgroup, with dysregulated cellular immunity and chronic inflammation. The inflammatory phenotype is commonly described as complicated CVID (CVIDCOMP/CVIDc), and is associated with autoimmune, autoinflammatory, granulomatous, lymphoproliferative, gastrointestinal, hepatic, and pulmonary complications. ^[83]^B3b^[238]^[244] Autoimmune or autoinflammatory manifestations are not restricted to patients with a previously established immunodeficiency diagnosis; in a large inborn-error-of-immunity cohort, these complications were present in 26.3% of patients and were the initial presentation in nearly half of affected individuals. ^[238]

The immune defect is therefore not simply quantitative hypogammaglobulinemia. CVID can involve altered T-cell and monocyte/macrophage homeostasis, abnormal B-cell differentiation, persistent immune activation, and defective coordination between adaptive and innate responses. ^[9]^C4^[83]^B3b^[239] Expansion of CD21low B cells is a recognized immunophenotypic feature of the immune-dysregulatory subgroup, particularly alongside chronic type 1 immune activation. ^[242] A related population, T-bet-high CD21low B cells, is associated with increased circulating and tissue IL-10; IL-10-producing cells include monocytes, T cells, and a subset of CD21low B cells. ^[245]^D These findings support a model in which compensatory or chronically stimulated immune-cell states may themselves participate in persistent inflammation rather than merely reflect antibody deficiency. ^[242]^[245]^D

T-cell, monocyte, and cytokine dysregulation

T-cell pathology is prominent in inflammation-prone CVID. An exploratory transcriptomic and proteomic study of isolated CD3+ T cells and CD14+ monocytes identified broader molecular alterations in CVID patients with autoimmune and inflammatory complications than in healthy controls, supporting cell-intrinsic abnormalities in both lymphoid and myeloid compartments. ^[83]^B3b The same study measured IL-1β, CXCL10, IL-18, and CXCL9 as candidate inflammatory mediators, indicating that inflammasome-, interferon-, and chemokine-linked pathways are being investigated as components of CVIDCOMP biology; the available abstract does not establish that each mediator is uniformly elevated in all patients. ^[83]^B3b

Serum cytokine profiling has also been evaluated as a potential surrogate for flow-cytometric identification of complicated CVID, particularly where access to lymphocyte-subset testing is limited. ^[244] This supports the clinical concept that systemic cytokine patterns may reflect immune dysregulation, but cytokine testing should not be interpreted as a universal replacement for cellular phenotyping because the study assessed diagnostic utility retrospectively. ^[244]

Expansion of terminally differentiated or senescent-like CD57+ CD8+ T cells has been specifically investigated in CVID. This population has been associated with granuloma or lymphadenopathy and with cytomegalovirus (CMV) positivity, linking chronic antigenic stimulation or viral latency with altered cytotoxic T-cell homeostasis. ^[239] CMV latency may also shape antigen-specific cellular immunity: in predominantly antibody-deficient patients with inborn errors of immunity, vaccine-induced CD4+ T-cell responses were evaluated together with CMV-specific responses, demonstrating the importance of viral history when interpreting cellular immune function. ^[235]^B2c

Metabolic and microbiome-associated inflammation

The tryptophan–kynurenine pathway is a candidate bridge between chronic immune activation, monocyte/T-cell biology, and intestinal microbial imbalance in CVID. A 2025 study measured pathway metabolites and neopterin in CVID cohorts specifically to test relationships with inflammatory and immunologic phenotypes and gut dysbiosis. ^[9]^C4 These data support investigation of immunometabolism as a disease-modifying axis, but metabolite associations should not be treated as proof of causality. ^[9]^C4

Microbial ecology may also influence immune-dysregulatory disease. In CTLA4 deficiency, a related inborn error of immune regulation characterized by regulatory T-cell dysfunction and intestinal immune infiltration, Veillonella and Streptococcus were identified as microbiome biomarkers distinguishing affected individuals from healthy cohorts. ^[236]^C Because CTLA4 deficiency is genetically and mechanistically distinct from most CVID, these findings are mechanistic context rather than direct evidence that the same organisms cause CVID. ^[236]^C

Genetic heterogeneity and CVID-like disease

Some patients labelled as having CVID have monogenic disorders that produce a CVID-like phenotype, making genetic testing important for mechanism-based classification and treatment selection. ^[44]^C4 Examples include NFKB1 haploinsufficiency, caused by monoallelic loss-of-function variants and associated with hypogammaglobulinemia or a CVID-like phenotype; in one Japanese series, clinical penetrance was 52%, illustrating variable expression even within a defined genetic disorder. ^[246]^D Hypomorphic IL2RG variants can produce adult-onset antibody deficiency with moderate CD4+ T-cell lymphopenia rather than classic severe combined immunodeficiency, demonstrating that partial cytokine-receptor dysfunction can present along a CVID spectrum. ^[40]^C4 IRF2BP2 variants have likewise been investigated as a form of CVID with inflammation through clinical and functional studies of 34 individuals from 18 families. ^[47]^C4

STAT3 gain-of-function disease may be diagnosed after years of a CVID label and can redirect therapy toward the underlying pathway, emphasizing that persistent inflammation, unusual infections, or atypical lymphoproliferation should prompt genetic reassessment. ^[44]^C4 Automated flow-cytometry analysis incorporating lymphocyte profiles, age, and immunoglobulin levels is being developed to improve screening for lymphoid primary immunodeficiencies, but such tools assist rather than replace clinical and molecular diagnosis. ^[240]

Mechanistic boundaries and differential context

Gastrointestinal villous atrophy and chronic diarrhea can arise in both CVID and autoimmune enteropathy, reflecting overlapping consequences of immune-mediated intestinal injury but requiring clinicopathologic discrimination. ^[243] Good syndrome is a separate adult-onset immunodeficiency associated with thymoma, hypogammaglobulinemia, and combined B- and T-cell defects; it should not be assumed to represent CVID biology. ^[81]^C4 Similarly, hereditary angioedema and CVID can coexist and produce overlapping gastrointestinal or treatment-related diagnostic confusion without sharing the same immune mechanism. ^[54]^C4 Histologic gastrointestinal injury after CAR-T-cell therapy or anti-CD38 treatment represents an acquired treatment-associated context and is not evidence for CVID pathogenesis. ^[237]^C

Finally, impaired humoral responses do not imply absent cellular immunity. Across heterogeneous inborn errors of immunity, repeated SARS-CoV-2 vaccination studies found lower antibody responses but measurable or enhanced T-cell responses in some cohorts, including patients with CVID; individual responses remain variable. ^[241]^C^[67]^B2b Thus, CVID pathophysiology is best understood as a spectrum combining defective antibody generation with context-dependent T-cell, B-cell, myeloid, cytokine, metabolic, microbial, and genetic abnormalities. ^[9]^C4^[83]^B3b^[242]^[245]^D

Mechanistic domains implicated in complicated CVID

Domain	Evidence and interpretation
B-cell dysregulation	Expansion of CD21low and T-bet-high CD21low B cells, with IL-10 production by multiple immune-cell sources. ^[242]^[245]^D
T-cell dysregulation	CD57+ CD8+ T-cell expansion and broader molecular abnormalities in T cells from CVID patients with inflammatory complications. ^[83]^B3b^[239]
Myeloid and cytokine activation	Altered CD14+ monocyte profiles and investigation of IL-1β, IL-18, CXCL9, and CXCL10; serum cytokines may aid complication phenotyping. ^[83]^B3b^[244]
Immunometabolism and microbiome	Tryptophan–kynurenine metabolites, neopterin, and gut dysbiosis are being evaluated as correlates of inflammation; CTLA4-deficiency microbiome findings provide related mechanistic context. ^[9]^C4^[236]^C
Genetic heterogeneity	NFKB1, IL2RG, IRF2BP2, and STAT3 pathway defects can create CVID-like or inflammatory phenotypes with variable penetrance. ^[40]^C4^[44]^C4^[47]^C4^[246]^D

Epidemiology, Etiology & Risk Factors

▸CVID is heterogeneous; a tertiary-care Indian cohort reported recurrent respiratory infections in 84.2%, gastrointestinal complications in 45%, autoimmune manifestations in 21%, and severe disease in 66.6% [29].
▸Compared with CVID, isolated IgG, combined IgG/IgM, and IgG-subclass deficiencies generally show fewer respiratory infections and less bronchiectasis but more mucocutaneous herpes simplex reactivation [103,249].
▸Immune-dysregulation phenotypes, gastrointestinal or hepatic disease, lymphoproliferation, autoimmunity, and malignancy identify higher-burden CVID or IEI subsets [16,97,102,108,238].
▸Chronic kidney disease was reported in 6.27% of adults with CVID and was associated with older age and cardiometabolic or treatment-related factors [94].

CP Clinical Pearl: CVID should not be defined solely by recurrent infections: immune dysregulation, autoimmunity, lymphoproliferation, gastrointestinal or hepatic disease, and malignancy substantially influence phenotype and prognosis [16,97,102,108,238].

! Warning: Many cited prevalence estimates come from tertiary-care or broader IEI cohorts and may not represent population-level CVID risk [29,101,238,253,293].

Epidemiology

Common variable immunodeficiency (CVID) is a clinically heterogeneous primary antibody deficiency characterized by impaired immunoglobulin production and recurrent infections ^[29]^C4. In a 10-year Indian cohort of 150 patients, the median age at diagnosis was 18 years, 62% were male, recurrent respiratory tract infections occurred in 84.2%, gastrointestinal complications in 45%, and autoimmune manifestations in 21%; 66.6% were classified as having a severe phenotype ^[29]^C4. These figures derive from a tertiary-care cohort and should not be interpreted as population prevalence estimates ^[29]^C4.

A long-term New Zealand cohort enrolled 108 patients, representing approximately 70% of patients known to have CVID nationally; the cohort identified a notably greater prevalence of CVID among Indigenous Māori patients and a high prevalence of bronchiectasis and complete IgA deficiency ^[253]^C. The available report does not provide the corresponding population denominators or exact ethnicity-specific prevalence estimates, limiting assessment of the magnitude of this association ^[253]^C.

CVID is distinguished clinically from isolated IgG deficiency, combined IgG/IgM deficiency, and IgG-subclass deficiency. Compared with CVID, patients with isolated IgG or combined IgG/IgM deficiency had fewer respiratory and gastrointestinal infections, whereas recurrent mucocutaneous herpes simplex reactivation was more frequent; splenomegaly and immune thrombocytopenic purpura were more common in CVID ^[249]. Similarly, IgG-subclass deficiencies were associated with fewer recurrent lower respiratory tract infections and less bronchiectasis than CVID, while mucocutaneous herpes simplex reactivation was more frequent ^[103]^B3b. These comparisons support the importance of accurate phenotypic classification when estimating disease burden ^[103]^B3b^[249].

Etiology and biological heterogeneity

The available evidence supports CVID as a heterogeneous disorder involving impaired antibody production and clinically variable infection, autoimmune, inflammatory, gastrointestinal, hepatic, and lymphoproliferative phenotypes ^[29]^C4^[94]^B2b^[102]^B3b^[239]. The distinction between infection-predominant CVID and CVID with immune dysregulation is clinically important because immune-dysregulation complications are associated with greater mortality risk ^[16]^B3b. Expansion of CD57-positive CD8 T cells has been studied as a marker of altered immune homeostasis in CVID and has been associated with granuloma or lymphadenopathy and positive cytomegalovirus status ^[239].

Some disorders may resemble or overlap with CVID but have distinct molecular etiologies. Heterozygous germline CTLA4 variants cause CTLA-4 insufficiency, whereas biallelic LRBA variants cause LRBA deficiency; both produce immune dysregulation, autoimmunity, lymphoproliferation, and immunodeficiency ^[292]. In CTLA4 deficiency, intestinal dysbiosis involving genera such as Veillonella and Streptococcus was associated with disease discrimination and severity, supporting a possible microbiome contribution to intestinal pathology, although these findings should not be generalized to genetically undefined CVID ^[236]^C.

Risk factors and associated clinical burden

Disease severity is influenced by the presence of immune-dysregulation complications rather than infection susceptibility alone ^[16]^B3b. In a large tertiary-center analysis, premature mortality was specifically investigated among patients with CVID complicated by immune dysregulation, reflecting the higher-risk nature of this phenotype ^[16]^B3b. Gastrointestinal and hepatic disease are also important severity markers: a Spanish adult cohort reported that up to one-third of patients with CVID may develop gastrointestinal or hepatic manifestations, and evaluated enteropathy and liver disease as prognostic factors ^[102]^B3b.

Infection-related risk is determined by the underlying hypogammaglobulinemia and associated immune abnormalities. Among immunoglobulin-treated patients with hypogammaglobulinemia, a prospective study included 53 individuals with primary hypogammaglobulinemia, including 32 with CVID; the study specifically addressed persistent or recurrent Campylobacter carriage and gastrointestinal inflammation ^[250]^C. Cryptosporidiosis is uncommon but clinically relevant in IEI: in the French national registry, 41 of 10,004 patients had proven cryptosporidiosis, corresponding to approximately 0.41% of the registry and 27.5% of patients with a recorded parasitic infection; most affected patients had combined immunodeficiency rather than CVID ^[101]^B3b.

Geographic exposure and host factors may modify infectious risk. In a cohort of 117 adults with IEI, tuberculosis screening incorporated exposure history, symptoms, tuberculin testing, repeat testing after an initial indeterminate or low result, and chest imaging; the study highlights the need to interpret tuberculosis testing in the context of immune dysfunction rather than relying on a single screening result ^[248]^C.

Noninfectious complications contribute substantially to morbidity. Autoimmune or autoinflammatory manifestations occurred in 26.3% of 825 Algerian patients with IEI and were the initial presentation in nearly half of affected patients, although these figures include multiple IEI categories and are not CVID-specific ^[238]. Endocrine disease is also recognized across IEI; reported endocrinopathy prevalence in the broader IEI literature is approximately 27–32.5%, while a dedicated adult CVID study was undertaken to evaluate autoimmune, non-autoimmune, and glucocorticoid-associated endocrinopathies ^[293]^C. Malignancy is an additional concern: retrospective IEI cohorts have documented neoplasia in adults ^[97]^C4, and patients with primary immunodeficiency have been specifically evaluated for increased head-and-neck cancer risk ^[108]^B3b. Chronic kidney disease occurred in 23 of 367 adults with CVID (6.27%) in a multicenter Italian study and was associated with older age, hypertension, diabetes, dyslipidemia, ultrasound abnormalities, and predominant intravenous immunoglobulin use ^[94]^B2b.

Selected epidemiologic and risk estimates

Finding	Estimate or association	Reference
Severe phenotype in an Indian CVID cohort	66.6%	^[29]^C4
Respiratory tract infections in the same cohort	84.2%	^[29]^C4
Gastrointestinal complications in the same cohort	45%	^[29]^C4
Autoimmune manifestations in the same cohort	21%	^[29]^C4
Chronic kidney disease in an Italian adult CVID cohort	6.27% (23/367)	^[94]^B2b
Cryptosporidiosis among patients in the French IEI registry	0.41% (41/10,004)	^[101]^B3b
Reported endocrinopathy prevalence across IEI literature	27–32.5%	^[293]^C

Clinical Presentation

▸CVID commonly presents with recurrent respiratory infections, but gastrointestinal disease, autoimmunity, splenomegaly, lymphoproliferation, inflammation, and liver involvement are frequent components of the phenotype. [29][102][249]
▸Recurrent respiratory tract infections were reported in 84.2% of a 150-patient Indian cohort, while gastrointestinal complications occurred in 45% and autoimmune manifestations in 21%. [29]
▸Autoimmune or autoinflammatory disease may precede recognition of immunodeficiency; it was the initial presentation in nearly half of affected patients in a cohort of 825 patients with inborn errors of immunity. [238]
▸Unusual infections, severe viral disease, cytopenias, enteropathy, liver disease, or lymphoproliferation should prompt consideration of a monogenic CVID-like disorder or phenocopy and support genetic testing. [44][120][37][38][81]

Dx Diagnostic Essentials: Do not regard autoimmunity, enteropathy, liver disease, splenomegaly, or lymphoproliferation as atypical enough to exclude CVID; these are recognized components of its heterogeneous clinical presentation. [29][102][249]

! Warning: An unusual infection pattern, severe viral infection, thymoma, prominent inflammation, or marked lymphoproliferation may indicate a CVID phenocopy or monogenic disorder such as STAT3 gain-of-function, CTLA4 haploinsufficiency, LRBA deficiency, IRF2BP2-associated disease, or Good syndrome. [44][120][37][38][81]

Overall phenotype

Common variable immunodeficiency (CVID) is a heterogeneous, predominantly antibody-deficiency disorder characterized by impaired immunoglobulin production and recurrent infections, but its presentation also includes gastrointestinal disease, autoimmunity, lymphoproliferation, inflammatory complications, and hepatic involvement. ^[29]^C4^[255] Disease severity and age at recognition vary substantially; in a 150-patient Indian cohort, the median age at diagnosis was 18 years, and 66.6% of patients were classified as having a severe phenotype. ^[29]^C4 Moroccan nationwide data likewise emphasize broad clinical, immunological, and genetic heterogeneity. ^[255]

Infections

Recurrent respiratory tract infections are the dominant presenting feature. In the Indian cohort, 84.2% of patients had recurrent respiratory tract infections. ^[29]^C4 Respiratory and gastrointestinal infections were more frequent in CVID than in cohorts with isolated IgG deficiency or combined IgG/IgM deficiency, supporting the importance of distinguishing CVID from milder hypogammaglobulinemic phenotypes. ^[249] Persistent or severe infection may occur despite immunoglobulin replacement; a reported patient with longstanding CVID developed recurrent pneumonia, chronic sinusitis, osteomyelitis, sepsis, and repeated lower-respiratory-tract infections after COVID-19. ^[119]^C4

Patients may also develop infections that suggest an alternative or additional immune defect. Nontuberculous lymphadenitis contributed to recognition of a STAT3 gain-of-function disorder in a patient previously labeled as having CVID, illustrating that unusual infections should prompt reassessment and genetic testing. ^[44]^C4 Severe or atypical viral disease, including recurrent mucocutaneous herpes simplex reactivation, was more common in isolated IgG or combined IgG/IgM deficiency than in CVID in one comparative cohort. ^[249] Severe varicella-zoster virus and Pseudomonas aeruginosa infection were reported in a patient with CTLA4 haploinsufficiency presenting with an immunodeficiency phenotype. ^[38]^C4

Tuberculosis should be considered according to epidemiologic exposure, symptoms, and local prevalence. A 2026 study of 117 patients with inborn errors of immunity, with a median age of 35 years, assessed exposure history, symptoms, tuberculin skin testing, and chest imaging; patients with an initial tuberculin reaction of 0–4 mm underwent repeat testing after 1–4 weeks. ^[248]^C These data support structured tuberculosis assessment in patients with antibody deficiency, particularly when respiratory or constitutional symptoms are unexplained. ^[248]^C

Gastrointestinal and hepatic manifestations

Gastrointestinal involvement is common and clinically important. In the Indian cohort, gastrointestinal complications occurred in 45% of patients. ^[29]^C4 A Spanish adult cohort noted that up to approximately one-third of patients with CVID may develop gastrointestinal or hepatic manifestations and evaluated enteropathy and liver involvement using objective clinical, endoscopic, histologic, radiologic, or hemodynamic findings. ^[102]^B3b CVID-associated enteropathy and liver disease are therefore potential components of the presenting phenotype rather than merely late complications. ^[102]^B3b

Hepatic involvement may be clinically occult. A study of patients with CVID or agammaglobulinemia evaluated the Enhanced Liver Fibrosis score and shear-wave elastography in individuals without previously documented liver fibrosis, reflecting the need to consider non-invasive assessment when liver disease is suspected. ^[136]^C4 Chronic infection and inflammation can rarely progress to secondary AA amyloidosis; one patient with longstanding CVID, recurrent pneumonia, sinusitis, osteomyelitis, and sepsis developed nephrotic syndrome, with renal and gastric biopsies confirming AA amyloidosis. ^[119]^C4

Autoimmunity, inflammation, and lymphoproliferation

Autoimmune and inflammatory disease is a major part of the clinical spectrum. In a cohort of 825 patients with inborn errors of immunity, autoimmune and/or autoinflammatory manifestations occurred in 26.3%, and these manifestations were the initial presentation in nearly half of affected patients. ^[238] In the Indian CVID cohort, autoimmune manifestations occurred in 21% of patients. ^[29]^C4 Splenomegaly and immune thrombocytopenic purpura were more frequent in CVID than in isolated IgG or combined IgG/IgM deficiency. ^[249]

Autoimmune cytopenias may be prominent or recurrent. Among 47 adult CVID patients with autoimmune thrombocytopenia, 25.5% experienced thrombocytopenic episodes during a 64-month observation period. ^[234]^B2b The occurrence of autoimmune thrombocytopenia should therefore not be interpreted as excluding CVID. ^[234]^B2b Reported CVID-spectrum presentations also include chronic immune thrombocytopenia, hemorrhagic complications, lymphoproliferation, arthritis, primary biliary cholangitis, and systemic inflammation. ^[120]^C4^[37]^C4

The inflammation-prone CVID phenotype is associated with distinct T-cell and monocyte transcriptional and proteomic profiles, supporting biologic heterogeneity among patients with immune dysregulation. ^[83]^B3b Clinical manifestations may include splenic enlargement and inflammatory or autoimmune disease; a newly described “sponge-like” splenic sonographic pattern has been reported in patients with immune dysregulation disorders, although its diagnostic significance remains under investigation. ^[36]^B3b

When the presentation suggests a monogenic disorder or phenocopy

Genetic testing is considered standard of care in newly diagnosed CVID, and it remains relevant in patients with longstanding diagnoses when infection patterns, autoimmunity, lymphoproliferation, or inflammation are atypical. ^[44]^C4 CTLA4 haploinsufficiency, LRBA deficiency, STAT3 gain-of-function, and IRF2BP2 variants can produce CVID-like phenotypes with hypogammaglobulinemia, impaired memory B-cell or plasmablast differentiation, autoimmunity, inflammation, or lymphoproliferation. ^[120]^C4^[44]^C4^[37]^C4^[38]^C4 Good syndrome should be considered when adult-onset hypogammaglobulinemia accompanies thymoma and combined B- and T-cell immune defects, particularly with multiple pulmonary infections. ^[81]^C4

Clinical manifestations reported in contemporary cohorts

Manifestation	Reported evidence
Recurrent respiratory tract infection	84.2% in a 150-patient Indian CVID cohort. ^[29]^C4
Gastrointestinal complications	45% in the same cohort; up to approximately one-third may develop GI or hepatic manifestations in another adult cohort. ^[29]^C4^[102]^B3b
Autoimmune manifestations	21% in the Indian cohort; autoimmune/autoinflammatory manifestations occurred in 26.3% of 825 patients with IEI. ^[29]^C4^[238]
Autoimmune thrombocytopenia	Episodes occurred in 25.5% of 47 adult CVID patients followed for 64 months. ^[234]^B2b
Severe phenotype	66.6% in the Indian cohort; median age at diagnosis was 18 years. ^[29]^C4

Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup

▸Use quantitative IgG, IgA, and IgM together with clinical phenotype and functional antibody assessment to distinguish CVID from isolated IgG or combined IgG/IgM deficiency. [249]
▸Do not exclude allergic disease because of CVID or low IgE; allergy testing must be phenotype- and exposure-directed. [257]
▸Consider hereditary angioedema, drug reactions, mast-cell disorders, autoimmunity, and infection in patients labelled as having antibiotic or other immediate allergy. [54]
▸Include lymphocyte flow cytometry and consider cellular antigen-response testing when the phenotype suggests broader immune dysfunction. [240] [235]
▸Repeat a TST after 1–4 weeks when the initial result is 0–4 mm in an IEI tuberculosis-screening pathway. [248]
▸Pursue genetic testing in newly diagnosed, atypical, longstanding, or immune-dysregulated CVID-like disease. [44] [246] [38] [120]

Dx Diagnostic Essentials: A CVID label should trigger evaluation for immune dysregulation and monogenic CVID-like disorders, not only measurement of immunoglobulin concentrations. [44] [246] [38] [120]

CP Clinical Pearl: Allergic symptoms, antibiotic reactions, angioedema, and recurrent infection can overlap clinically; interpret allergy tests only after defining the phenotype and considering hereditary angioedema and other mimics. [54] [257]

Diagnostic scope

CVID should be evaluated as a heterogeneous antibody-deficiency phenotype rather than as a diagnosis based solely on recurrent infection. The workup should integrate quantitative immunoglobulins, functional antibody assessment, lymphocyte immunophenotyping, immune-dysregulation findings, exclusion of secondary hypogammaglobulinemia, and genetic investigation when clinically appropriate. Recent comparative data indicate that isolated IgG deficiency and combined IgG/IgM deficiency have generally fewer respiratory and gastrointestinal infections than CVID, whereas CVID more often has splenomegaly and immune thrombocytopenic purpura; recurrent mucocutaneous herpes simplex reactivation was more frequent in the non-CVID groups. These distinctions support repeat and comparative immune testing rather than automatic classification as CVID. ^[249]

Allergy assessment and interpretation

A careful history should distinguish immediate hypersensitivity, delayed drug reactions, recurrent infection, autoimmune disease, hereditary angioedema, and mast-cell disorders. Angioedema and antibiotic-associated symptoms may mimic allergy; a reported antibiotic hypersensitivity was ultimately diagnostically challenging in a patient with concurrent type I hereditary angioedema and CVID. ^[54]^C4 Therefore, testing should be guided by the reaction phenotype and timing rather than by the label of “allergy” alone. ^[54]^C4

Allergic disease is not excluded by CVID. In a prospective study of 60 adults with CVID, an allergic disease was documented in 26.6%; allergic rhinitis was the most frequent reported condition (56.2%), followed by bronchial asthma (12.5%). Serum IgE and IgA were specifically evaluated as potential biomarkers, but the abstract does not establish a universal IgE-based diagnostic threshold or a definitive predictive role for either analyte. ^[257] Consequently, total IgE, allergen-specific IgE, and skin testing should be interpreted in the context of symptoms, exposure history, and the patient’s broader immunoglobulin phenotype; a low or undetectable IgE result should not by itself invalidate a convincing clinical history. ^[257]

Core immune-function workup

Initial laboratory assessment should characterize the humoral defect with serum IgG, IgA, and IgM and should separate CVID from isolated IgG or combined IgG/IgM deficiency. The comparative cohort found clinically and immunologically meaningful differences among these groups, supporting measurement of all major immunoglobulin classes rather than reliance on IgG alone. ^[249] Results should be interpreted alongside infection pattern, gastrointestinal disease, splenomegaly, autoimmune cytopenias, and mucocutaneous viral disease, because these features help identify CVID-associated immune dysregulation and alternative CVID-like disorders. ^[249]

Flow-cytometric immunophenotyping is an important component of evaluation. Standardized multiparameter flow cytometry has been used to screen for lymphoid primary immunodeficiencies, and the PIDgeon pipeline was developed to classify immune profiles and suggest PID subtypes using flow-cytometric data, age, and immunoglobulin levels. Its development dataset included 74 healthy controls and 399 patients, including 281 lymphoid-PID and 118 non-PID individuals, and used EuroFlow-standardized data. ^[240] Automated interpretation may improve reproducibility and reporting, but it complements rather than replaces clinical review and laboratory expertise. ^[240]

Functional cellular testing may be required when the phenotype is not confined to antibody deficiency. In predominantly antibody-deficient IEI, antigen-specific CD4+ T-cell responses to SARS-CoV-2 vaccination and CMV peptides have been measured by stimulation-index analysis of effector-memory CD4+ T cells, demonstrating a framework for assessing cellular immune responsiveness in addition to serum antibodies. ^[235]^B2c Interpretation should account for CMV latency, which was specifically investigated as a modifier of T-cell responses in this population. ^[235]^B2c

Infection-directed testing

The infection history should determine targeted microbiologic and immune evaluation. For gastrointestinal symptoms or persistent diarrhea, prospective stool screening in immunoglobulin-treated hypogammaglobulinemic patients used culture, PCR, and fecal calprotectin; the cohort included 32 patients with primary CVID and demonstrated the feasibility of systematic Campylobacter investigation during Ig replacement therapy. ^[250]^C Tuberculosis assessment in IEI included exposure and symptom history, tuberculin skin testing, and chest imaging with radiography and, where available, computed tomography. If the initial TST measured 0–4 mm, it was repeated after 1–4 weeks. ^[248]^C

Immune dysregulation, organ involvement, and genetics

The immune-function workup should actively search for autoimmune and inflammatory complications. Autoimmune thrombocytopenia is frequent in CVID, and a prospective cohort defined clinically important episodes as a platelet count <50,000/µL with bleeding or <20,000/µL with or without bleeding. ^[234]^B2b Splenic ultrasound is commonly used in IEI surveillance, and a newly described “sponge-like” splenic microtexture has been reported in immune-dysregulation disorders, although its diagnostic significance remains investigational. ^[36]^B3b

Gastrointestinal and hepatic assessment is warranted because up to one-third of patients with CVID may develop GI or hepatic manifestations; CVID-associated enteropathy and liver involvement were defined using objective clinical, endoscopic, histologic, radiologic, or hemodynamic findings. ^[102]^B3b Non-invasive hepatic assessment has also been studied using the Enhanced Liver Fibrosis score and shear-wave elastography in CVID and agammaglobulinemia, but validation in these disorders remains limited. ^[136]^C4

Genetic testing is considered standard of care for newly diagnosed CVID patients in the cited practice-based report, and testing should also be reconsidered in longstanding or atypical cases. A patient diagnosed with CVID more than a decade earlier was subsequently found to have a STAT3 gain-of-function variant after unusual infections prompted reassessment. ^[44]^C4 Relevant CVID-like disorders include NFKB1 haploinsufficiency, which showed only 52% clinical penetrance in one Japanese series, and CTLA4 haploinsufficiency or LRBA deficiency, which may combine hypogammaglobulinemia with autoimmunity, inflammation, lymphoproliferation, or severe infection. ^[246]^D ^[38]^C4 ^[120]^C4 Expanded testing is therefore particularly appropriate when immune dysregulation, unusual infections, organ disease, family history, or atypical immunophenotyping is present. ^[44]^C4 ^[246]^D ^[38]^C4 ^[120]^C4

Patient-centred diagnostic practice

Because IEI diagnostics and management impose substantial physical, psychological, and socioeconomic burdens, assessment should incorporate health-related quality of life and shared decision-making. Recommended instruments include SF-36, Pediatric Quality of Life Inventory, and Patient-Reported Outcome Measurement Information System tools, selected according to age and clinical context. ^[258]^D

Reference-supported components of the CVID immunodiagnostic workup

Domain	Evaluation supported by the cited evidence
Humoral immunity	Serum IgG, IgA, and IgM; classification against isolated IgG and combined IgG/IgM deficiency; functional antibody assessment. ^[249]
Allergy and mimics	Reaction history, exposure and timing review, targeted skin or serum allergen testing, and consideration of hereditary angioedema and nonallergic mimics. ^[54]^C4 ^[257]
Cellular immunity	Multiparameter lymphocyte flow cytometry; antigen-specific CD4+ T-cell response testing when indicated. ^[240] ^[235]^B2c
Infection screening	Exposure and symptom assessment, TST with repeat testing for an initial 0–4 mm result, chest radiography and/or CT, and targeted stool testing including culture and PCR. ^[248]^C ^[250]^C
Immune dysregulation and organ disease	Assessment for autoimmune cytopenias, splenic abnormalities, enteropathy, liver involvement, and hepatic fibrosis. ^[234]^B2b ^[36]^B3b ^[102]^B3b ^[136]^C4
Etiologic diagnosis	Genetic testing for monogenic IEI, especially in atypical or dysregulated CVID-like phenotypes. ^[44]^C4 ^[246]^D ^[38]^C4 ^[120]^C4

Severity, Grading & Risk Stratification

▸CVID severity is multidimensional; no universally validated severity-grading system is established in the cited evidence [29][147][148].
▸A severe phenotype in one 150-patient cohort was reported in 66.6% of patients, with recurrent respiratory infections in 84.2%, gastrointestinal complications in 45%, and autoimmunity in 21% [29].
▸GLILD, progressive pulmonary disease, multisystem immune dysregulation, liver fibrosis, and prolonged or recurrent viral infection identify higher-risk phenotypes [139][147][148][155][261].
▸Only 68.3% of patients in one CVID vaccine cohort seroconverted after BNT162b2 vaccination, with median antibody titres 83-fold lower than controls [142].
▸sBCMA, switched-memory B cells, CD21low B cells, microbiome measures, and liver elastography are promising adjuncts but are not validated standalone severity grades [136][236][264][265].

Dx Diagnostic Essentials: Patients with CVID plus lymphoproliferation, autoimmune cytopenias, severe enteropathy, granulomatous disease, or disproportionate multisystem involvement should be evaluated for an alternative or monogenic inborn error of immunity, including ALPS-like disorders and CTLA4 deficiency [33][236].

HY High Yield: GLILD and progressive pulmonary abnormalities should trigger structured assessment with clinical review, HRCT, and pulmonary-function testing; no single CT, laboratory, or biomarker threshold independently defines overall CVID severity [139][147][148].

! Warning: The proposed lower-, intermediate-, and higher-risk categories are pragmatic and non-validated. They should support surveillance and referral decisions, not replace individualized specialist assessment [33][147].

Overview

CVID is clinically heterogeneous, and severity is better understood as a multidomain phenotype than as a single immunoglobulin threshold. Relevant domains include infection burden, chronic pulmonary disease, immune dysregulation, gastrointestinal and hepatic involvement, malignancy, vaccine responsiveness, and cumulative organ damage ^[29]^C4^[261]^C. No universally accepted, prospectively validated CVID severity-grading system is established in the cited evidence; therefore, risk assessment should be individualized and reassessed longitudinally ^[29]^C4^[147]^A1c^[148]^B2b.

Practical severity domains

Infectious phenotype: Recurrent or severe respiratory infections remain a dominant marker of clinically significant disease. In a 150-patient Indian cohort, recurrent respiratory tract infections occurred in 84.2%, while 66.6% were classified by the investigators as having a severe phenotype; gastrointestinal complications occurred in 45% and autoimmune manifestations in 21% ^[29]^C4. Oropharyngeal microbial-community perturbations were associated with clinical and immunological features and with risk of acute respiratory infection in a prospective study of 72 adults with CVID ^[260]. These findings support incorporating infection frequency, hospitalization, antimicrobial exposure, bronchiectasis, chronic colonization, and microbiome-associated susceptibility into severity assessment, although microbiome measures are not yet validated grading tools ^[260].

Pulmonary involvement: Chronic pulmonary disease is a major determinant of morbidity and mortality in primary antibody deficiency ^[148]^B2b. GLILD is a particularly important high-risk complication because it is associated with substantial morbidity and mortality, although the cited guideline was developed primarily to standardize screening and diagnosis rather than to provide a validated severity score ^[147]^A1c^[139]^C4. The 2026 ERS clinical practice guideline used GRADE methodology and multidisciplinary consensus because diagnostic and management practice had varied substantially between centres and countries ^[147]^A1c. High-resolution CT, pulmonary function testing, and assessment for lymphadenopathy, splenomegaly, granulomatous disease, and lymphocytic interstitial involvement should therefore be interpreted together rather than used as isolated severity markers ^[147]^A1c^[139]^C4.

In primary antibody deficiency, a retrospective longitudinal study with a median follow-up of 7.4 years sought clinical and laboratory predictors of pulmonary CT abnormalities requiring regular surveillance, underscoring that CT-screening intensity should be risk-based rather than identical for all patients ^[148]^B2b. High-dose systemic corticosteroids, defined as ≥0.3 mg/kg prednisone equivalent, were evaluated as first-line treatment for GLILD in 56 patients, with repeated HRCT or pulmonary-function assessment available in 39; the study addressed treatment response but does not establish a universal prognostic grading threshold ^[139]^C4.

Immune dysregulation and lymphoproliferation: Autoimmunity, autoimmune cytopenias, lymphoproliferation, enteropathy, granulomatous disease, and organ-specific inflammation may indicate a more complex phenotype than infection-predominant CVID ^[29]^C4^[33]^B2b. A prospective paediatric cohort showed that autoimmune lymphoproliferative syndrome-like disorders can be more severe than classic ALPS and that lymphoproliferation plus autoimmune cytopenia should prompt evaluation for an inborn error of immunity rather than automatic attribution to CVID ^[33]^B2b. CTLA4 deficiency is an important phenocopy or genetic explanation for severe immune dysregulation; intestinal disease, immune-cell infiltration, autoimmunity, and extraintestinal involvement characterize the disorder, and gut microbiome/metabolome signatures involving genera such as Veillonella and Streptococcus were reported as potential markers distinguishing severe CTLA4 deficiency ^[236]^C. These biomarkers remain investigational and should not be used alone to grade CVID ^[236]^C.

Hepatic and gastrointestinal risk: Liver disease is a recognized CVID complication, but prevalence, mechanisms, and prognostic implications remain incompletely defined ^[261]^C. In a small 2026 study of 22 patients with CVID and 9 with agammaglobulinemia without previously documented liver fibrosis, enhanced liver fibrosis testing and shear-wave elastography were investigated as non-invasive measures; neither approach is yet a validated CVID severity scale ^[136]^C4. Gastrointestinal involvement should be graded by symptoms, nutritional consequences, inflammatory or infectious evaluation, histology when indicated, and evidence of systemic immune dysregulation rather than by a single laboratory value ^[29]^C4^[261]^C.

Biomarkers and prognostic modifiers

Reduced soluble B-cell maturation antigen concentrations have been associated with greater severity in primary antibody deficiencies; in the COV-AD study, sBCMA was significantly reduced in primary antibody deficiency compared with healthy controls, and it was examined alongside vaccine responses and disease complications ^[264]. A separate exploratory study combined sBCMA, summed kappa-plus-lambda light chains, switched-memory B cells, and the VISUAL score to distinguish CVID from selective IgA deficiency, secondary immunodeficiency, and healthy controls, but these markers remain diagnostic or exploratory rather than validated prognostic grades ^[265]. Reduced switched-memory B-cell compartments and increased CD21low B-cell frequencies may identify immune dysfunction; notably, a cohort of 50 patients with CVID found that only 68.3% seroconverted after BNT162b2 vaccination, with median antibody titres 83-fold lower than healthy controls, and elevated CD21low B-cell frequency was associated with poorer vaccine immunity ^[142]^B2b. Vaccine antibody response should therefore inform risk counselling but should not replace clinical phenotyping ^[59]^B2b^[142]^B2b.

Infection-specific risk

CVID is associated with increased risk of prolonged SARS-CoV-2 infection, reinfection, and adverse outcomes ^[259]. A Danish nationwide cohort found increased risks of first infection and reinfection compared with matched controls ^[155]^B2b. Vaccination remains clinically relevant despite impaired responses: the BNT162b2 study documented heterogeneous humoral responses and evaluated cellular immunity, while broader primary-antibody-deficiency data support individualized preventive and early-treatment planning ^[59]^B2b^[142]^B2b. Tuberculosis risk assessment should be exposure- and symptom-based and may require imaging because diagnostic performance of tuberculin testing can be limited in inborn errors of immunity ^[248]^C.

Suggested risk categories

A practical, non-validated framework is: lower risk, infection-predominant disease without established organ damage; intermediate risk, recurrent or severe infections with bronchiectasis, persistent gastrointestinal disease, autoimmune cytopenia, impaired vaccine responses, or abnormal pulmonary imaging; and higher risk, GLILD or progressive lung-function decline, significant liver disease or fibrosis, multisystem immune dysregulation, severe lymphoproliferation, recurrent opportunistic or prolonged viral infection, or established malignancy ^[29]^C4^[139]^C4^[147]^A1c^[148]^B2b^[155]^B2b^[261]^C. These categories should guide surveillance intensity, specialist referral, and investigation for monogenic immune-dysregulation disorders, but they are not substitutes for validated prospective scoring systems ^[33]^B2b^[147]^A1c.

Practical multidomain risk stratification

Domain	Lower/intermediate-risk features	Higher-risk features
Infection	Infrequent, non-severe infections without organ damage ^[29]^C4	Recurrent/severe or prolonged infections, reinfection, opportunistic infection, or hospitalization ^[29]^C4^[155]^B2b^[259]
Lung	Normal or stable imaging and pulmonary function ^[147]^A1c^[148]^B2b	GLILD, bronchiectasis, abnormal HRCT, or declining pulmonary function ^[139]^C4^[147]^A1c^[148]^B2b
Immune dysregulation	Isolated or limited autoimmunity ^[29]^C4	Multilineage cytopenias, lymphoproliferation, enteropathy, granulomatous disease, or suspected CTLA4-related disease ^[33]^B2b^[236]^C
Liver/GI	No persistent organ dysfunction ^[261]^C	Fibrosis, portal-hypertension features, progressive liver disease, severe enteropathy, or nutritional compromise ^[136]^C4^[261]^C
Biomarkers	Preserved vaccine response and less abnormal B-cell phenotype ^[142]^B2b^[264]^[265]	Poor vaccine response, increased CD21low B cells, reduced sBCMA, or markedly abnormal switched-memory B cells ^[142]^B2b^[264]^[265]

Acute Management & Anaphylaxis Pathway

▸The supplied evidence does not provide a CVID-specific anaphylaxis medication algorithm; suspected anaphylaxis requires immediate institutional emergency management and specialist review [247][156][269].
▸CVID and other IEI patients may have impaired, heterogeneous, or waning antibody responses after COVID-19 vaccination despite detectable or robust T-cell responses [65][67][173][193][267][268][271][272][273].
▸In an Italian IEI cohort, SARS-CoV-2 hospitalization occurred in 20.17% of patients; older age and chronic lung disease were associated with worse outcomes, and CVID comprised 65% of affected adults [194].
▸Shortage-related SCIg reduction was studied only in selected stable adults with low infection burden and IgG trough **≥700 mg/dL**, or **≥900 mg/dL** under specified conditions; the reduction was **15 mg/kg/week** [247].
▸Suspected immune thrombotic thrombocytopenic purpura in CVID requires urgent disease-specific specialist management; therapeutic plasma exchange was used successfully in a reported pediatric case [175].

! Warning: Do not extrapolate the SCIg dose-reduction strategy to patients with active infection, recent significant infections, or clinical instability; the evidence applies to a selected stable population [247].

CP Clinical Pearl: A poor vaccine antibody response does not necessarily indicate absent cellular immunity in CVID or other IEI, because multiple cohorts demonstrated measurable or robust T-cell responses despite reduced humoral responses [65][67][173][193][267][268][271][272][273].

Dx Diagnostic Essentials: In acute illness, assess for both infection and non-infectious immune complications because CVID has a heterogeneous spectrum with infectious and immune-mediated morbidity [270].

Scope and immediate priorities

Patients with common variable immunodeficiency (CVID) may present with acute infection, COVID-19, an immune-mediated complication, or a reaction temporally associated with immunoglobulin replacement therapy (IgRT). The supplied evidence does not provide a drug-by-drug anaphylaxis algorithm, dosing schedule for emergency medications, or validated CVID-specific emergency thresholds; therefore, suspected anaphylaxis should be managed immediately according to the institution’s current emergency anaphylaxis protocol, with early involvement of allergy/immunology and critical-care teams where clinically indicated ^[247]^C^[194]^C4^[270].

At first assessment, document airway, breathing, circulation, mental status, oxygenation, temperature, haemodynamic status, exposure history, timing of symptom onset, current IgRT route and dose, recent vaccination, and infection symptoms. This structured assessment is particularly important because CVID has a heterogeneous clinical spectrum, and infectious complications commonly coexist with non-infectious immune disorders ^[270]. Review recent antimicrobial use and previous acute-care presentations, because patients subsequently diagnosed with CVID had higher antibiotic exposure than matched controls during the preceding three years ^[168]^B3b.

Suspected anaphylaxis or acute infusion-related reaction

If symptoms are compatible with anaphylaxis during or shortly after IVIg or SCIg administration, stop the suspected infusion or injection, summon emergency assistance, assess airway and circulation immediately, and follow the local anaphylaxis pathway without waiting for laboratory confirmation. The supplied CVID studies do not establish a CVID-specific alternative to standard emergency treatment, nor do they define a validated role for serum immunoglobulin levels, complement testing, or vaccine antibody titres in the initial recognition of anaphylaxis ^[156]^C4^[247]^C^[269]^C.

After stabilization, record the product name, concentration, batch, route, administration rate, dose, timing, co-medications, symptoms, treatment, and outcome. Refer the patient for specialist review before further IgRT. Any decision to restart, change product, alter the route, or use a modified administration plan should be individualized; the cited studies describe replacement and immunomodulatory use of IVIg or SCIg but do not provide a universal rechallenge protocol ^[156]^C4^[247]^C^[269]^C.

Acute infection and COVID-19 pathway

Evaluate promptly for bacterial, viral, and respiratory infection, using examination, appropriate microbiology, imaging, and organ-function assessment according to the clinical syndrome. In an Italian IEI cohort, 20.17% of patients required hospital admission for SARS-CoV-2 infection; older age and chronic lung disease were associated with worse outcomes, and CVID represented 65% of affected adults ^[194]^C4. This supports a low threshold for early clinical review and escalation when respiratory symptoms, hypoxaemia, dehydration, altered mental status, or systemic deterioration develops, although the cited study does not define a CVID-specific admission rule ^[194]^C4.

Do not interpret a weak or absent post-vaccination antibody response as proof of absent cellular protection. Across CVID and other IEI cohorts, antibody responses were reduced or heterogeneous, while vaccine-associated T-cell responses were frequently detectable or robust; repeated vaccination improved or increased measurable humoral responses in several studies ^[65]^B2b^[67]^B2b^[173]^C4^[193]^B2b^[267]^C^[268]^[271]^[272]^[273]. Conversely, antibody quality, memory B-cell recall, neutralization, and durability may remain impaired in CVID, and responses decline over time, supporting continued clinical vigilance despite vaccination ^[65]^B2b^[67]^B2b^[173]^C4^[193]^B2b^[267]^C^[268]^[272].

IgRT during acute illness and dose decisions

IgRT remains a central treatment for hypogammaglobulinaemic primary immunodeficiency and is associated with reduced infection rates and mortality in the background evidence summarized by the dose-reduction study ^[247]^C. Do not apply a shortage-related SCIg dose reduction automatically during acute infection or clinical deterioration. The studied reduction strategy was limited to adults receiving SCIg for at least six months who had low recent infection burden, IgG trough levels of ≥700 mg/dL (or ≥900 mg/dL under specified conditions), and no significant infection during the preceding six months; the planned reduction was 15 mg/kg/week, equivalent to 60 mg/kg/month ^[247]^C. These eligibility criteria describe a selected stable population and should not be extrapolated to acutely unwell patients ^[247]^C.

Acute immune-mediated complications

CVID can be complicated by autoimmune disease, and rare severe presentations may require disease-specific emergency treatment. A reported child with CVID and immune thrombotic thrombocytopenic purpura recovered after therapeutic plasma exchange; the condition was associated with reduced ADAMTS13 activity, platelet consumption, microvascular thrombosis, and organ injury ^[175]^C4. Suspected thrombotic microangiopathy therefore requires urgent specialist assessment and disease-specific management rather than escalation of replacement IgRT alone ^[175]^C4.

Evidence boundary

The supplied references do not establish CVID-specific emergency antibiotic regimens, antiviral choices, epinephrine doses, observation periods after anaphylaxis, or criteria for ICU admission. These decisions must follow current institutional emergency protocols and specialist advice, while the evidence above informs risk recognition, vaccination interpretation, IgRT continuity, and escalation ^[65]^B2b^[67]^B2b^[175]^C4^[194]^C4^[247]^C.

Evidence-informed acute decision points

Clinical situation	Immediate approach	Evidence boundary
Suspected anaphylaxis during or after IgRT	Stop exposure, activate emergency response, assess airway and circulation, and follow the institutional anaphylaxis pathway	CVID-specific emergency drug doses and rechallenge criteria were not supplied ^[156]^C4^[247]^C^[269]^C
Acute COVID-19 or respiratory infection	Prompt clinical assessment and early escalation when respiratory or systemic deterioration occurs	Hospitalization risk data come from an IEI cohort and do not define a CVID-specific admission threshold ^[194]^C4
Stable patient considered for SCIg reduction	Confirm selected-study criteria before considering reduction	Criteria included ≥700 mg/dL IgG trough, or ≥900 mg/dL in specified circumstances, and no significant infection for six months ^[247]^C
Suspected iTTP or thrombotic microangiopathy	Urgent haematology/immunology assessment and disease-specific treatment	Therapeutic plasma exchange was reported in one pediatric CVID case ^[175]^C4

Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics

▸Immunoglobulin replacement is standard therapy and convincingly reduces pulmonary infections, but its effect on chronic rhinosinusitis is less certain [296].
▸High-dose corticosteroids for GLILD were studied at **≥0.3 mg/kg prednisone equivalent**; evidence supports formal HRCT and pulmonary-function monitoring, but does not define a universal regimen [139].
▸Rituximab plus azathioprine has retrospective evidence in GLILD, while case-level evidence shows that rituximab responses in CVID-associated lymphoid interstitial pneumonia may be temporary [141,187].
▸A supervised **1-month** chest-physical-therapy program was associated with better FEV1 at **12 months** in a mixed pediatric chronic-lung-disease cohort that included CVID [183].
▸MV130 remains investigational after a small observational proof-of-concept study in **20** CVID patients [274].
▸Biologics such as omalizumab should be reserved for defined comorbid disease; successful use in CVID is supported by case-report evidence only [185].

CP Clinical Pearl: Adequate trough IgG does not exclude recurrent respiratory infections or noninfectious CVID complications; persistent disease should prompt phenotype-directed evaluation rather than automatic escalation of replacement alone [274,296].

! Warning: Rituximab and other immunosuppressive therapies can be associated with incomplete or temporary responses in CVID-associated lymphoid lung disease and should be managed by specialist teams with infection surveillance [141,187].

Management principles

Long-term management of common variable immunodeficiency (CVID) should be individualized according to the patient’s infectious, inflammatory, autoimmune, pulmonary, gastrointestinal, and lymphoproliferative phenotype. CVID is heterogeneous: patients may develop recurrent or chronic infections, autoimmune disease, inflammatory complications, lymphoma, and other malignancies; cohort-based phenotypes and immunologic laboratory findings can help stratify risk, and mortality was reported to increase 11-fold when at least one high-risk phenotype—such as cytopenia—was present ^[90]^D5.

Infection avoidance and respiratory care

Immunoglobulin replacement is a standard treatment for CVID and other primary antibody deficiencies. Evidence summarized in a retrospective study supports reduction of pulmonary infections, whereas evidence for preventing sinus infections or controlling chronic rhinosinusitis (CRS) is more limited ^[296]^D. In patients with persistent or refractory CRS, primary immunodeficiency should be considered and evaluation should include immunologic assessment; a systematic review identified 39 eligible studies addressing immune dysfunction, diagnostic work-up, and medical or surgical treatment in primary immunodeficiency-associated CRS ^[181]^B2a.

Respiratory prevention should also include individualized airway-clearance measures. In a randomized study involving children with chronic pulmonary disease, including 12 children with CVID, a 1-month hospital-supervised chest-physical-therapy program produced a significantly higher forced expiratory volume in 1 second at 12 months than unsupervised home therapy, although the cohort combined CVID with Kartagener syndrome and primary ciliary dyskinesia ^[183]^A1b.

Repeated imaging should balance clinical need against cumulative radiation exposure. Lung MRI was investigated as a radiation-free alternative to CT in 23 patients with primary immunodeficiency, including CVID; MRI was weaker than CT for detecting bronchiectasis and other airway abnormalities, so it should not automatically replace CT when detailed airway assessment is required ^[182]^C4.

Patients with primary immunodeficiencies, including CVID, may be susceptible to fungal disease involving organisms such as Candida and Aspergillus, although the reported spectrum and risk vary by the underlying immune defect ^[189]^D5. This supports careful clinical assessment of persistent, atypical, or refractory respiratory infection rather than assuming that adequate IgG replacement eliminates all infectious risk ^[189]^D5^[296]^D.

Immunoglobulin replacement and investigational prophylaxis

Immunoglobulin replacement addresses antibody deficiency but does not necessarily prevent all respiratory morbidity or noninfectious complications. Persistent or recurrent respiratory tract infections may occur despite adequate trough IgG levels and can impair quality of life ^[274]. A proof-of-concept observational study evaluated a trained-immunity-based polybacterial preparation, MV130, in 20 CVID patients; 10 patients with recurrent respiratory tract infections received treatment for 3 months and were followed for up to 12 months ^[274]. Because this was an observational, small proof-of-concept study, MV130 should be regarded as investigational rather than established definitive therapy ^[274].

GLILD and lymphoid pulmonary disease

Granulomatous and lymphocytic interstitial lung disease (GLILD) is a major cause of morbidity and mortality in CVID ^[139]^C4. Systemic corticosteroids are recommended as first-line treatment, but the efficacy evidence has historically been limited ^[139]^C4. A study evaluated high-dose corticosteroids, defined as ≥0.3 mg/kg prednisone equivalent, in 56 patients who had not received other immunosuppressive therapy at the time; repeated HRCT or pulmonary-function testing was available for 39 patients ^[139]^C4. These data support structured assessment with HRCT and pulmonary-function testing when corticosteroids are used, while the supplied evidence does not establish a universal dose, duration, relapse strategy, or steroid-sparing regimen ^[139]^C4.

For selected patients with GLILD that is severe, persistent, or steroid-refractory, rituximab-based treatment has been studied. A retrospective study assessed combined rituximab and azathioprine, with pulmonary-function tests and HRCT obtained before treatment and more than 6 months afterward ^[141]^C4. The study was designed to determine whether combination therapy improved pulmonary function or radiographic abnormalities; its retrospective design means that treatment should be directed by an experienced immunology/pulmonology team rather than applied routinely to all CVID patients ^[141]^C4. A separate CVID-associated lymphoid interstitial pneumonia case reported temporary remission after low-dose rituximab at 150 mg/m² weekly, followed by relapse after 6 months; subsequent standard-dose treatment at 375 mg/m² did not provide durable remission in the reported course ^[187]^C4.

Biologics and immune-modulating therapies

Biologic therapy should be reserved for a clearly defined comorbidity or immune-mediated complication, with infection risk and immunoglobulin status considered before treatment. Omalizumab was reported successful in a young woman with CVID and refractory chronic spontaneous urticaria despite immunoglobulin replacement and prior treatment attempts; this is case-report evidence and does not establish routine use in CVID ^[185]^C4.

CVID-associated autoimmune and inflammatory disease may require immunosuppression, but treatment should be phenotype-specific. A pediatric case demonstrated that corticosteroid treatment for systemic lupus erythematosus manifestations was followed by disappearance of clinical and laboratory features, while the patient subsequently developed CVID in the setting of IgA and IgG2 deficiency ^[186]^C4. This illustrates the need to distinguish treatment-responsive autoimmune disease from the underlying antibody deficiency rather than using corticosteroids as replacement for immunoglobulin therapy ^[186]^C4.

Practical conclusion

Definitive long-term care combines regular immunoglobulin replacement, infection-focused prevention, airway clearance when indicated, surveillance of pulmonary disease and noninfectious complications, and specialist-directed immunosuppression for GLILD or other inflammatory manifestations ^[90]^D5^[139]^C4^[181]^B2a^[183]^A1b^[296]^D. Rituximab, azathioprine, corticosteroids, or other biologics should be considered only for defined complications and with explicit monitoring for infection, relapse, pulmonary-function change, and treatment toxicity ^[139]^C4^[141]^C4^[185]^C4^[187]^C4.

Evidence-informed long-term interventions

Intervention	Evidence and appropriate interpretation
Immunoglobulin replacement	Standard CVID therapy; reduces pulmonary infections, but benefit for CRS is less established ^[296]^D.
Chest physical therapy	Supervised therapy for 1 month improved 12-month FEV1 in a mixed pediatric cohort including CVID ^[183]^A1b.
Corticosteroids for GLILD	First-line treatment evaluated at ≥0.3 mg/kg prednisone equivalent; monitor with HRCT and PFTs ^[139]^C4.
Rituximab ± azathioprine	Retrospective GLILD evidence; use selectively because response and durability are not established for every patient ^[141]^C4^[187]^C4.
MV130	Investigational trained-immunity-based prophylaxis; small observational proof-of-concept study ^[274].
Omalizumab	Case-report evidence for refractory urticaria in CVID, not routine CVID therapy ^[185]^C4.

Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution

▸IgRT by IVIg or SCIg is the cornerstone of infection prevention in CVID; available evidence supports similar efficacy, while SCIg offers fewer systemic adverse events and greater autonomy. [254]
▸SCIg local reactions may affect adherence, so initiation should include individualized counseling and assessment of patient- and site-level risk factors. [251]
▸Autoimmune thrombocytopenia remains a distinct management problem: 25.5% of 47 adults with CVID and autoimmune thrombocytopenia experienced episodes during 64 months of observation. [234]
▸Cryptosporidiosis and tuberculosis require targeted evaluation in patients with IEI or CVID-like disease; repeat tuberculin testing after 1–4 weeks is used when the initial reaction is 0–4 mm. [101][248]
▸Genetic testing can identify actionable alternative or monogenic diagnoses; pathogenic or likely pathogenic variants were found in 19% of a 72-patient Russian IEI cohort. [297]
▸Persistent inflammation, autoimmune cytopenias, lymphoproliferation, endocrine disease, or malignancy should prompt diagnostic reassessment rather than being attributed automatically to uncomplicated CVID. [97][119][238][293]

Dx Diagnostic Essentials: A longstanding CVID diagnosis should be revisited when infections are unusual, immune dysregulation is prominent, or lymphoproliferation, cytopenias, endocrine disease, or malignancy develops; genetic testing may identify a directed-treatment disorder. [44][38][120][107]

! Warning: Do not interpret negative or minimally reactive tuberculosis testing in IEI in isolation; the cited strategy includes exposure assessment, symptoms, repeat TST after 1–4 weeks for an initial 0–4 mm result, and chest imaging. [248]

CP Clinical Pearl: SCIg can improve autonomy and reduce systemic adverse events, but local reactions may compromise adherence and should be anticipated during shared treatment planning. [251][254]

Management principles

CVID management should be individualized around infection prevention, recognition of immune dysregulation, surveillance for malignancy, and reassessment of the underlying diagnosis. Immunoglobulin replacement therapy (IgRT), administered intravenously (IVIg) or subcutaneously (SCIg), remains the cornerstone of infection prevention in CVID; available real-world evidence describes broadly similar efficacy between routes, with SCIg associated with fewer systemic adverse events and greater patient autonomy. ^[254] Treatment selection should therefore incorporate clinical phenotype, venous access, infusion burden, patient preference, adherence, local expertise, and tolerability. ^[254]

Immunoglobulin replacement: IVIg and SCIg

SCIg is an established alternative to IVIg for primary and secondary immunodeficiency and may improve safety and quality of life, although local adverse reactions can limit uptake and adherence. ^[251] A nationwide Spanish multicenter study specifically evaluated clinical, anatomical, psychosocial, and geographical factors associated with local reactions, supporting anticipatory counseling and individualized site- and patient-level planning when SCIg is initiated. ^[251] The available evidence does not establish a universal route, dose, or serum-IgG target for every CVID patient; therapy should instead be adjusted to infection control and patient-specific response. ^[254]

Autoimmune cytopenias require separate assessment from routine replacement dosing. In a prospective observational cohort of 47 adults with CVID and autoimmune thrombocytopenia, 27 patients received SCIg and 20 received IVIg; over 64 months, 12 patients (25.5%) experienced autoimmune thrombocytopenia episodes according to predefined platelet and bleeding criteria. ^[234]^B2b These data address comparative occurrence during replacement therapy but do not demonstrate that either maintenance route replaces disease-directed treatment for an acute, severe, or bleeding-associated episode. ^[234]^B2b

Infection prophylaxis and targeted screening

IgRT reduces the infectious burden that results from impaired antibody production, but persistent or atypical infections should prompt microbiological investigation and evaluation for additional cellular, genetic, or immune-regulatory defects. ^[254] Cryptosporidiosis is a documented opportunistic infection across inborn errors of immunity: in the French CEREDIH registry, 41 of 10,004 patients (0.41%) had proven cryptosporidiosis, and 149 patients (approximately 1.4%) had at least one parasitic infection. ^[101]^B3b The cryptosporidiosis cases were diagnostically heterogeneous and included combined immunodeficiency and hyper-IgM syndromes, emphasizing that prolonged watery diarrhea or exposure-compatible illness in a patient labeled as having CVID should not automatically be attributed to routine gastrointestinal infection. ^[101]^B3b

Tuberculosis evaluation should be exposure- and symptom-informed rather than based on a single test alone. A 2026 adult IEI cohort used exposure history, symptom assessment, tuberculin skin testing, repeat testing after 1–4 weeks when the initial reaction measured 0–4 mm, and chest imaging, including radiography and computed tomography when available. ^[248]^C These methods provide a practical framework for screening patients with CVID or a CVID-like phenotype, particularly when epidemiological risk, constitutional symptoms, pulmonary findings, or immunosuppressive treatment increases concern. ^[248]^C

Immune dysregulation, immunosuppression, and surveillance

Infection prevention must be balanced against the substantial burden of autoimmunity and autoinflammation in IEI. In an Algerian cohort of 825 patients, autoimmune and/or autoinflammatory manifestations occurred in 217 (26.3%), and these findings were the initial presentation in nearly half of affected patients. ^[238] Autoimmune cytopenias, inflammatory disease, lymphoproliferation, and chronic infection should therefore trigger reassessment for a monogenic disorder rather than being treated as unrelated complications. ^[238]

Long-term corticosteroid exposure may itself contribute to endocrine morbidity, while endocrinopathies in adult CVID may also be autoimmune or non-autoimmune. ^[293]^C Endocrine symptoms and treatment-related complications should consequently be actively reviewed during follow-up, especially in patients requiring prolonged glucocorticoid therapy. ^[293]^C Chronic uncontrolled infection or inflammation can produce serious secondary complications; a reported CVID case developed AA amyloidosis after prolonged recurrent infections and inflammatory disease, illustrating the importance of controlling persistent inflammatory activity and investigating proteinuria or nephrotic syndrome promptly. ^[119]^C4

Malignancy surveillance is also required. In a retrospective adult IEI cohort, 40 of 355 patients had neoplasia, with a median age of 51.58 years among affected patients. ^[97]^C4 New lymphadenopathy, splenomegaly, cytopenias, constitutional symptoms, or persistent organ enlargement should not be attributed automatically to CVID-associated lymphoproliferation. ^[97]^C4

Immune reconstitution and diagnostic refinement

Genetic testing is considered standard of care for newly diagnosed CVID patients, and it remains appropriate in longstanding cases when the phenotype is unusual, severe, treatment-refractory, or suggestive of immune dysregulation. ^[44]^C4 Whole-genome sequencing in a Russian IEI cohort identified pathogenic or likely pathogenic variants in 14 of 72 patients (19%), including variants in BTK, CYBB, CHD7, AIRE, ATM, SBDS, NFKB1, and CTLA4. ^[297]^C A CVID label may therefore conceal disorders requiring disease-specific management, including STAT3 gain-of-function, CTLA4 haploinsufficiency, LRBA deficiency, or NFKB1-related disease. ^[44]^C4^[38]^C4^[120]^C4^[107]^C4

Disease-specific immune dysregulation can include severe infection, autoimmune cytopenia, inflammation, lymphoproliferation, and malignancy, as described for CTLA4, LRBA, and NFKB1 disorders. ^[38]^C4^[120]^C4^[107]^C4 Genetic clarification may open the way to directed therapy, as illustrated by a patient initially diagnosed with CVID who was later found to have STAT3 gain-of-function disease. ^[44]^C4 Conversely, secondary hypogammaglobulinemia should be reconsidered when thymoma and combined B- and T-cell defects suggest Good syndrome rather than CVID. ^[81]^C4

COVID-19 vaccine responses are heterogeneous in IEI. A study of 114 IEI patients and 38 healthy controls assessed Spike-specific and cytomegalovirus-specific memory CD4+ T-cell responses after two mRNA vaccine doses, supporting evaluation of cellular as well as antibody responses when vaccine protection is clinically important. ^[235]^B2c The cited evidence does not define a universal revaccination or prophylactic-antibody strategy for CVID. ^[235]^B2c Apparent drug allergy or recurrent swelling should likewise be diagnostically reviewed: concurrent hereditary angioedema and CVID can mimic antibiotic hypersensitivity, while allergic disease was documented in 26.6% of 60 adult CVID patients in a prospective study. ^[54]^C4^[257]

Evidence-informed management priorities

Clinical priority	Evidence-informed action
Antibody failure and recurrent infection	Use IVIg or SCIg as IgRT; individualize route and follow clinical infection control. ^[254]
SCIg initiation	Counsel regarding local adverse reactions and adherence; assess patient-specific risk factors. ^[251]
Autoimmune thrombocytopenia	Monitor platelet counts and bleeding; do not assume maintenance IgRT substitutes for acute disease-directed treatment. ^[234]^B2b
Persistent diarrhea or exposure risk	Consider Cryptosporidium and other opportunistic infections. ^[101]^B3b
TB risk or compatible symptoms	Combine exposure history, symptoms, TST with repeat testing when indicated, and chest imaging. ^[248]^C
Atypical or multisystem phenotype	Pursue genetic testing and reassess for monogenic IEI or immune dysregulation. ^[44]^C4^[297]^C
Chronic inflammation or new organ dysfunction	Evaluate for complications including AA amyloidosis, endocrinopathy, or malignancy. ^[119]^C4^[293]^C^[97]^C4

Complications, Comorbidities & Iatrogenic Risks

▸CVID complications commonly include recurrent respiratory infection, gastrointestinal disease, autoimmunity, inflammation, hepatic disease, endocrinopathy, lymphoproliferation, and malignancy.[29][19][293]
▸Gastrointestinal complications occurred in 45% and autoimmune manifestations in 21% of a 150-patient CVID cohort.[29]
▸Cryptosporidiosis and Campylobacter are important gastrointestinal infectious risks in antibody deficiency, although available cohorts are broader than CVID alone.[101][250]
▸CTLA-4 insufficiency and LRBA deficiency can mimic or overlap with CVID through combined immunodeficiency, autoimmunity, and lymphoproliferation.[292]
▸Subcutaneous immunoglobulin may cause local adverse reactions, while prolonged glucocorticoid therapy may cause endocrinopathies.[251][293]
▸Hepatic manifestations in CVID are associated with mortality and worse hospital outcomes in nationwide data.[19]

! Warning: Do not extrapolate evidence from broader IEI, PID, or secondary hypogammaglobulinemia cohorts directly to CVID-specific incidence or prognosis.[97][101][108][250]

Dx Diagnostic Essentials: Consider a monogenic immune-dysregulation disorder, particularly CTLA-4 insufficiency or LRBA deficiency, when CVID-like disease is accompanied by prominent autoimmunity or lymphoproliferation.[292]

Overview

CVID is a heterogeneous antibody-deficiency disorder in which complications extend beyond recurrent infection to gastrointestinal, pulmonary, hepatic, autoimmune, inflammatory, endocrine, lymphoproliferative, and malignant disease.^[29]^C4^[253]^C^[255]^[256]^C In a 150-patient Indian cohort, respiratory infections occurred in 84.2%, gastrointestinal complications in 45%, and autoimmune manifestations in 21%; 66.6% were classified as having a severe phenotype.^[29]^C4 A Moroccan multicenter cohort likewise evaluated CVID across clinical, immunological, and genetic domains, emphasizing substantial phenotypic and genetic heterogeneity.^[255]

Infectious and gastrointestinal complications

Hypogammaglobulinemia increases susceptibility to gastrointestinal infection, including Campylobacter. A prospective study of 73 immunoglobulin-treated patients with hypogammaglobulinemia included 32 individuals with CVID and used stool culture, PCR, fecal calprotectin, and immune profiling to assess Campylobacter carriage or infection; repeat sampling was performed after 6–12 months in 38 participants.^[250]^C The study included both primary and secondary hypogammaglobulinemia, so its findings should not be generalized exclusively to CVID.^[250]^C

Cryptosporidiosis is an uncommon but clinically important opportunistic infection in inborn errors of immunity. In the French CEREDIH registry, 149 of 10,004 patients (approximately 1.4%) had at least one proven parasitic infection, and 41 (27.5% of those with parasitic infection; 0.41% of the total registry) had cryptosporidiosis.^[101]^B3b Most affected patients had combined immunodeficiency, including hyper-IgM syndromes; the registry therefore demonstrates the infection burden across IEI rather than defining a CVID-specific rate.^[101]^B3b

Gastrointestinal disease is a major CVID comorbidity. In a 2025 cohort, 45% of patients had gastrointestinal complications.^[29]^C4 CVID-associated enteropathy has been investigated using duodenal and ileal biopsies: patients with enteropathy were compared with CVID patients without enteropathy, individuals with Crohn disease, and healthy controls, with analysis of mucosal T-cell phenotypes, maturation, and cytokine production.^[298]^C These findings support mucosal regulatory/effector T-cell imbalance as a potential component of enteropathy, although the biopsy study was small (11 CVID patients with enteropathy and 13 without).^[298]^C

Autoimmunity, inflammation, and lymphoproliferation

Autoimmune and autoinflammatory disease is a central noninfectious complication of IEI and CVID. In an Algerian cohort of 825 IEI patients, autoimmune and/or autoinflammatory manifestations occurred in 26.3%; autoimmune disease occurred in 19.8%, and autoimmune findings were the initial presentation in nearly half of affected patients.^[238] CVID patients with autoimmune or inflammatory complications show abnormalities involving T cells and monocytes, with exploratory molecular studies identifying altered transcriptional and proteomic profiles.^[83]^B3b Tryptophan–kynurenine metabolites have also been associated with inflammation, immune phenotypes, and gut microbial dysbiosis in CVID.^[9]^C4

Expansion of CD57+ CD8 T cells has been studied in 131 CVID patients followed for a median of 9 years and was associated in prior observations with granuloma/lymphadenopathy and positive CMV status.^[239] Reduced serum soluble BCMA has been investigated in primary and secondary antibody deficiency in relation to disease complications and vaccine responses; it is a research biomarker rather than an established standalone clinical risk classifier.^[264]

Some patients with CVID-like disease have monogenic immune-dysregulation disorders. CTLA-4 insufficiency and LRBA deficiency can produce autoimmunity, lymphoproliferation, and immunodeficiency.^[292] The ABACHAI trial is a prospective, open-label, single-arm phase IIa study evaluating 125 mg subcutaneous abatacept weekly for 12 months in genetically confirmed adult CTLA-4 insufficiency or LRBA deficiency with at least one clinically significant organ manifestation; its primary endpoint is safety.^[292] Abatacept has been used successfully and increasingly off-label in these disorders, but the trial population is genetically defined and should not be assumed to represent unselected CVID.^[292]

Hepatic, endocrine, and malignant complications

Hepatic manifestations are clinically important in CVID. A U.S. nationwide readmission-database analysis evaluated their prevalence, spectrum, correlates, and hospital outcomes; liver disease in CVID was associated with mortality and worse hospitalization outcomes.^[19]^C4 Accordingly, hepatic abnormalities should be treated as potentially prognostically significant rather than incidental findings.^[19]^C4

Endocrinopathies represent an additional comorbidity. A retrospective study of 95 adult CVID patients specifically examined autoimmune, non-autoimmune, and glucocorticoid-induced endocrinopathies, highlighting long-term steroid exposure as a potential contributor to endocrine morbidity.^[293]^C The study also addressed associated clinical and genetic characteristics, but its single-center retrospective design limits causal inference.^[293]^C

IEI is associated with increased malignancy risk. A single-center study of 355 adults with IEI identified 40 patients with neoplasia, with a median age of 51.58 years among those with malignancy.^[97]^C4 A separate comparative study evaluated head and neck cancer incidence in PID against the general population and compared outcomes in propensity-matched patients with and without PID, addressing a cancer site that is less well characterized than hematologic malignancy in PID.^[108]^B3b These studies support individualized, age-appropriate cancer surveillance, while their broader IEI/PID populations do not establish a CVID-specific incidence estimate.^[97]^C4^[108]^B3b

Iatrogenic risks and monitoring

Immunoglobulin replacement remains central to management but can cause treatment-related burden. Subcutaneous immunoglobulin is generally considered a safe alternative to intravenous therapy, yet local adverse reactions can affect adherence and clinician confidence; a multicenter Spanish study examined clinical, anatomical, psychosocial, and geographic factors associated with these reactions.^[251] Long-term glucocorticoid therapy may contribute to endocrine complications in CVID.^[293]^C Immunosuppressive or targeted therapy should therefore be guided by phenotype and genetic diagnosis, with abatacept evidence currently focused on CTLA-4 insufficiency and LRBA deficiency rather than routine CVID.^[292]^[293]^C

Risk stratification

Severity prediction remains imperfect. A machine-learning study of 150 CVID patients attempted to predict disease severity using clinical and immunological variables, but retrospective cohort models require external validation before directing individual care.^[29]^C4 Cytokine testing has been investigated as a potential alternative or adjunct when flow cytometry is unavailable for identifying complicated CVID, but it is not established as a replacement for comprehensive immunophenotyping.^[244] Clinical assessment should integrate infection history, enteropathy, autoimmunity, inflammation, lymphoproliferation, hepatic disease, endocrine effects, malignancy risk, and treatment toxicity.^[19]^C4^[29]^C4^[83]^B3b^[238]^[244]^[250]^C^[251]^[293]^C^[298]^C

Major complication domains and evidence

Domain	Evidence and clinical relevance
Infection	Respiratory infections occurred in 84.2% of one cohort; cryptosporidiosis occurred in 0.41% of a national IEI registry; Campylobacter was specifically investigated in immunoglobulin-treated hypogammaglobulinemia.^[29]^C4^[101]^B3b^[250]^C
Gastrointestinal	Gastrointestinal complications occurred in 45%; CVID-associated enteropathy has been linked to mucosal T-cell imbalance.^[29]^C4^[298]^C
Autoimmune/inflammatory	Autoimmune and/or autoinflammatory manifestations occurred in 26.3% of an IEI cohort; CVID inflammatory phenotypes show T-cell and monocyte abnormalities.^[238]^[83]^B3b
Hepatic	Hepatic manifestations in CVID were associated with mortality and worse hospital outcomes.^[19]^C4
Endocrine	Autoimmune, non-autoimmune, and glucocorticoid-induced endocrinopathies have been evaluated in adults with CVID.^[293]^C
Malignancy	IEI cohorts demonstrate neoplasia burden and specifically evaluate head and neck cancer risk.^[97]^C4^[108]^B3b
Treatment toxicity	Subcutaneous immunoglobulin may cause local reactions; long-term glucocorticoids may cause endocrinopathy.^[251]^[293]^C

Prognosis & Natural History

▸CVID prognosis is heterogeneous; immune-dysregulation complications (CVIDc) are associated with higher mortality than infection-only disease (CVIDio). [16]
▸Bronchiectasis was reported in **13.4% (197/1470)** of USIDNET-registered CVID patients. [283]
▸GLILD affects approximately **10–20%** of patients with CVID disorders and can impair exercise capacity, lung function, quality of life, and survival. [287][288]
▸Chronic enteropathy, permanent organ damage, older age, and frequent infections are associated with worse or more concerning quality-of-life outcomes. [286]
▸Cancer occurs more often in IEI than in immunocompetent populations and is an important cause of death; malignancy is a major CVID prognostic concern. [86][282]
▸CVID phenotypes and cellular immune abnormalities may evolve over time, including in association with CMV or EBV viremia. [280]

! Warning: Do not assume that immunoglobulin replacement eliminates long-term risk: immune dysregulation, bronchiectasis, GLILD, enteropathy, viral complications, organ damage, and malignancy may determine prognosis. [16][129][280][282][283]

CP Clinical Pearl: Longitudinal assessment should include complications and patient-reported outcomes, not infection frequency alone; quality of life may remain impaired because of chronic enteropathy, permanent organ damage, fatigue, or perceived health deterioration. [258][286]

Overview

Common variable immunodeficiency (CVID) has a heterogeneous, lifelong course characterized not only by recurrent or severe infection but also by immune dysregulation, organ damage, impaired quality of life, and malignancy risk. ^[16]^B3b^[86]^A1a^[282] Prognosis is therefore determined by the individual complication profile rather than by hypogammaglobulinemia alone. ^[16]^B3b^[286] Patients with an infection-only phenotype (CVIDio) generally have a more favorable prognosis than those with immune-dysregulation complications (CVIDc), who have higher mortality. ^[16]^B3b

Pulmonary disease and GLILD

Chronic respiratory disease is a major determinant of long-term morbidity. In the USIDNET registry, physician-reported bronchiectasis was present in 13.4% (197/1470) of patients with CVID; the study specifically evaluated its relationship with recurrent pulmonary infection and other respiratory comorbidities. ^[283] Bronchiectasis represents established structural lung disease and may contribute to persistent respiratory symptoms, recurrent infection, and progressive organ damage. ^[283]

Granulomatous-lymphocytic interstitial lung disease (GLILD) is a noninfectious immune-dysregulatory complication reported in approximately 10–20% of patients with CVID disorders. ^[288]^C It is clinically important because it may impair exercise capacity, pulmonary function, and health-related quality of life, and has historically been described as a potentially fatal complication. ^[287]^C^[288]^C Patients may report exertional dyspnea; prospective assessment has used the 6-minute walk test and the King's Brief Interstitial Lung Disease Questionnaire to quantify functional and quality-of-life outcomes. ^[288]^C

The 2026 ERS clinical practice guideline was developed because GLILD diagnosis and management previously varied substantially between centers and countries and lacked an accepted guideline. ^[147]^A1c The guideline uses evidence review, GRADE methodology, and multidisciplinary consensus to address screening and diagnosis in CVID. ^[147]^A1c Small retrospective series suggest that disease activity can improve with immunosuppression: in one six-patient series, first-line rituximab monotherapy was assessed using symptoms, quality of life, immune parameters, pulmonary function testing, and computed tomography. ^[287]^C However, the small sample size and observational design mean that treatment response and long-term prognosis remain uncertain. ^[287]^C

Infection-related trajectory

CVID can produce unusually prolonged or severe infections because impaired antibody responses may coexist with cellular immune abnormalities. ^[129]^B2b^[280] Campylobacter infection, which ordinarily resolves within 5–7 days in immunocompetent individuals, may be prolonged or severe in CVID and require antibiotics or more intensive treatment. ^[129]^B2b A retrospective cohort included 14 affected patients and 95 CVID controls, with a median follow-up exceeding 20 years, allowing assessment of clinical, immunologic, microbiologic, and treatment outcomes over an extended period. ^[129]^B2b

Viral complications may also influence the evolving phenotype. In a 31-patient retrospective CVID analysis, investigators evaluated cytomegalovirus and Epstein–Barr virus viremia in relation to immunophenotype, clinical outcome, and time-dependent changes in disease manifestations. ^[280] The study highlights that CVID-associated cellular immune defects and clinical phenotypes may change over time, although the available abstract does not establish a universal progression pattern. ^[280] Severe or unusual opportunistic infection should prompt reassessment of the diagnosis and immune phenotype, because Good syndrome—thymoma-associated immunodeficiency—can resemble CVID while involving combined B- and T-cell defects and may be misdiagnosed as CVID. ^[81]^C4^[212]^C4

Malignancy and immune dysregulation

Malignancy is an important adverse prognostic outcome in CVID and other inborn errors of immunity; systematic-review evidence identifies cancer as more frequent than in immunocompetent populations and as an important cause of death in IEI. ^[86]^A1a A multicenter CVID study evaluated hematologic and solid-organ malignancies and examined immune dysregulation as a possible risk factor for carcinogenesis. ^[282] The study reflects the current clinical view that autoimmune disease, lymphoproliferation, and malignancy are major noninfectious complications that increasingly influence prognosis. ^[282]

The available evidence does not support a single reliable risk score for premature death. A retrospective tertiary-center study compared patients with CVIDc who died prematurely with matched living CVIDc controls to identify clinical and laboratory indicators of excess mortality. ^[16]^B3b These findings support intensified longitudinal surveillance in CVIDc, but exploratory retrospective data should not be interpreted as establishing causality or a definitive prediction model. ^[16]^B3b

Quality of life and cumulative burden

CVID-related prognosis includes patient-reported health and functional status. In an eight-year observational study of 140 patients assessed twice yearly, more frequent infections, female sex, and chronic enteropathy were associated with worse global CVID-specific quality-of-life scores. ^[286] Permanent organ damage and older age increased the perceived risk of health deterioration, while chronic enteropathy was associated with fatigue. ^[286] These findings indicate that cumulative organ damage and gastrointestinal disease may remain clinically important even when acute infections are controlled. ^[286]

Neurologic and cognitive consequences are being investigated but remain incompletely defined. A retrospective cross-sectional study compared 35 patients with CVID with 40 age- and sex-matched healthy controls using Montreal Cognitive Assessment testing and automated segmentation of high-resolution brain MRI. ^[281] Because the study was cross-sectional and small, it cannot determine whether observed structural or cognitive differences predict future disability. ^[281] Current IEI practice increasingly emphasizes routine health-related quality-of-life assessment and shared decision-making alongside medical outcomes. ^[258]^D

Overall prognostic interpretation

The natural history of CVID is variable and may evolve from infection-predominant disease to a phenotype dominated by bronchiectasis, GLILD, enteropathy, autoimmunity, lymphoproliferation, viral complications, or malignancy. ^[16]^B3b^[129]^B2b^[280]^[282]^[283] The strongest adverse prognostic signals supported by the cited evidence are immune-dysregulation complications, permanent organ damage, chronic enteropathy, significant lung disease, and malignancy. ^[16]^B3b^[286]^[282]^[283] Prognosis should therefore be reassessed longitudinally using clinical complications, pulmonary function and exercise capacity when indicated, infection and viral history, organ-damage burden, malignancy surveillance, and patient-reported quality of life. ^[147]^A1c^[258]^D^[286]^[288]^C

Major prognostic domains in CVID

Domain	Evidence relevant to natural history
Immune dysregulation	CVIDc carries higher mortality than infection-only CVID. ^[16]^B3b
Structural lung disease	Bronchiectasis was reported in 13.4% of 1470 registry patients. ^[283]
GLILD	Reported in approximately 10–20%; associated with respiratory and quality-of-life burden. ^[287]^C^[288]^C
Infection	Campylobacter may be prolonged or severe; immunocompetent illness usually lasts 5–7 days. ^[129]^B2b
Malignancy	Cancer is more frequent in IEI than in immunocompetent populations and contributes importantly to mortality. ^[86]^A1a
Quality of life	Infections, chronic enteropathy, permanent organ damage, and older age are associated with worse perceived health or quality of life. ^[286]

Special Populations and Pregnancy

▸Pediatric CVID has high morbidity and mortality; switched memory B cells <5/mL identify highest-risk children.
▸Pregnancy in CVID is high-risk (preterm labour, preeclampsia, stillbirth) but fertility is normal; IVIG is safe and breastfeeding is protective.
▸Elderly patients present with more non-infectious features; comorbidities demand individualized immunoglobulin dosing and infection surveillance.

Dx Diagnostic Essentials: In children with recurrent sinopulmonary infections, failure to thrive, or autoimmune cytopenias, check immunoglobulin levels and switched memory B cells, CVID is often missed until irreversible lung damage occurs.

Prognosis in CVID varies by age at presentation and by the physiologic demands of pregnancy, aging, and immune compromise. These special populations require tailored diagnostic thresholds and modified strategies.

Pediatrics

In children, recurrent sinopulmonary infections are the most common presentation, but failure to thrive, autoimmune cytopenias, bronchiectasis, and growth hormone deficiency are seen ^[21]^C4. Diagnostic delay averages 8.9 years from symptom onset, and the clinical signature, frequency of common infections and antibiotic prescriptions, can be detected by machine learning up to 10 years before formal diagnosis ^[215]^B3b^[223]^B2b. Patients with <5 switched memory B cells/mL (Group I) are at higher risk for meningitis, sepsis, bronchiectasis, granulomatous lung disease, autoimmune cytopenias, and hematologic malignancies ^[77]^B2b. Severe fatigue affects nearly 20% of pediatric patients and is not related to disease activity ^[219]^B2c. Subcutaneous immunoglobulin (SCIG) is well tolerated even in children with comorbid bleeding disorders, enabling home therapy ^[159]^C4. Mortality is increased in pediatric-onset CVID, with death most often from infection, and lung disease (OR 5) and severe/opportunistic infection (OR 9) directly associated with mortality ^[171]^B2b. Early diagnosis and regular surveillance for noninfectious complications are paramount.

Pregnancy

Fertility in women with CVID is not decreased, but pregnancies carry significantly higher risks. In a cohort of 54 women with 115 pregnancies, complications included threat of preterm labour (p<0.0001), vaginal bleeding (p=0.0001), eclampsia/preeclampsia (p=0.009), and (p<0.0001) compared with the general population; low birth weight (<2500 g) was also more frequent (p<0.0001) ^[200]^B2b. The number of unsuccessful pregnancies was higher in symptomatic untreated women ^[200]^B2b.

Immunoglobulin replacement therapy (IgRT) should be continued throughout pregnancy. Intravenous immunoglobulin (IVIG), dosed to maintain trough IgG >500-700 mg/dL, is safe and has no moderate or severe adverse effects in pregnancy ^[200]^B2b. Cord/maternal blood ratios of total IgG and specific antibodies show good placental transfer ^[135]^C4. is encouraged: colostrum from CVID mothers contains protective antibodies that inhibit enteropathogenic E. coli adhesion, providing local protection for the infant ^[135]^C4. IgA deficiency was found in 23% of children born to CVID mothers, warranting follow-up ^[200]^B2b. A multidisciplinary team including maternal-fetal medicine, immunology, and neonatology is essential ^[137]^D5.

Elderly

CVID diagnosed after age 50 often presents with bronchitis, arthritis, depression, and fatigue rather than classic infection patterns ^[220]^B2b. Chronic lung disease, which increases with age, is a major risk factor for hospitalization (p=0.0008) ^[194]^C4. Comorbidities such as diabetes, , and renal impairment complicate management. IgG trough targets should be individualized, balancing infection prevention against volume overload risk. Subcutaneous immunoglobulin may be preferred to avoid hemodynamic stress of IVIG in frail patients. Elderly patients have higher rates of lymphoma than younger cohorts, though not always statistically significant ^[220]^B2b.

Immunocompromised Settings

Patients with CVID who require additional immunosuppression (e.g., for autoimmune complications or post-transplant) face compounded infection risk. SARS-CoV-2 infection can elicit robust T-cell responses even without antibody production in some CVID patients ^[221]^B3b. Mortality from in CVID is highest in those aged 50-60, dramatically exceeding general population rates (14.3% vs 0.6%) ^[194]^C4. Persistent vaccine-derived poliovirus infection, although rare, has been reported in CVID and may require novel antivirals such as remdesivir ^[177]^C4. Any addition of immunosuppressive therapy demands intensified surveillance and antimicrobial prophylaxis.

Pearl: Elderly patients present with more non-infectious features; comorbidities demand individualized immunoglobulin dosing and infection surveillance.

Prevention, Screening & Surveillance

▸IgRT remains central to infection prevention, but breakthrough respiratory infections can occur; surveillance must remain individualized. [254,299]
▸COVID-19 vaccine responses in CVID are heterogeneous: antibody responses may be weak, while T-cell responses can remain detectable. [65,173,193,271]
▸Booster doses can improve immune responses, including attenuated memory-B-cell responses, but repeated vaccination does not eliminate the need for individualized precautions. [193,241,268]
▸Long COVID was reported in 65.7% of an Italian CVID cohort; it was defined as symptoms persisting >12 weeks. [100]
▸TB screening in IEI should combine exposure and symptom assessment with TST and imaging; repeat TST after 1–4 weeks when the initial result is 0–4 mm. [248]
▸Gastric surveillance is important because precancerous lesions were found in approximately one-third of evaluated CVID patients undergoing upper gastrointestinal endoscopy. [290]
▸Monitor for autoimmune cytopenias, including recurrent thrombocytopenia, and adapt surveillance to each patient’s phenotype and genetic risk. [234,232]

! Warning: A negative or weak COVID-19 antibody response does not necessarily indicate absent vaccine-related protection because cellular immunity may be preserved; conversely, detectable antibody does not remove the need for individualized precautions in CVID. [65,173,193,241,271]

HY High Yield: For IEI patients with an initial TST of 0–4 mm, the reported TB-screening strategy repeated testing after 1–4 weeks and incorporated chest imaging when appropriate. [248]

Infection prevention and immunoglobulin replacement

Immunoglobulin replacement therapy (IgRT), administered intravenously or subcutaneously, remains the cornerstone of infection prevention in CVID. Real-world data support broadly comparable effectiveness of IVIg and SCIG, while SCIG is associated with fewer systemic adverse events and greater patient autonomy. ^[254] Despite IgRT, some patients with predominantly antibody deficiency continue to develop respiratory infections, including pneumonia; registry data therefore support individualized assessment of infection history, treatment adherence, comorbid lung disease, and other patient-specific risk factors rather than assuming that IgRT eliminates risk. ^[299]^C Patients receiving IgRT should have ongoing clinical surveillance for breakthrough respiratory infections and treatment complications. ^[254]^[299]^C

COVID-19 vaccination and post-exposure prevention

CVID and other inborn errors of immunity (IEI) are associated with increased risk from COVID-19, making vaccination and rapid access to clinical assessment important components of prevention. ^[59]^B2b^[193]^B2b^[241]^C After primary mRNA vaccination, antibody responses are heterogeneous in IEI and may be reduced or absent in CVID; however, cellular responses can be preserved, including in some patients without detectable antibodies. ^[65]^B2b^[173]^C4^[193]^B2b^[271] Antibody quality may also be impaired, with reduced antibody avidity and impaired B-cell recall memory despite a robust T-cell response in some CVID patients. ^[173]^C4

Protection should therefore not be judged from anti-spike antibody testing alone. ^[65]^B2b^[173]^C4^[271] A third mRNA dose can improve responses in CVID, and booster vaccination has been reported to restore an attenuated IgG1 memory-B-cell response in primary antibody deficiency. ^[193]^B2b^[268] Longer-term studies evaluated booster responses and clinical outcomes during the first year of the vaccination program, supporting continued rather than one-time vaccination strategies in IEI. ^[267]^C Data from a five-dose schedule similarly showed enhanced T-cell immunity but lower humoral responses in IEI than in healthy controls, reinforcing the need to maintain non-vaccine precautions and individualized medical planning even after repeated vaccination. ^[241]^C

Patients and clinicians should recognize that COVID-19 may be prolonged or followed by persistent symptoms. In a multicenter Italian cohort, 65.7% of 175 CVID patients reported long COVID, defined as symptoms lasting >12 weeks after infection; fatigue was the most frequent symptom. ^[100]^B2b Vaccination, early testing when symptomatic, prompt clinician contact, and individualized consideration of available COVID-19 treatments are therefore particularly important in CVID. ^[59]^B2b^[100]^B2b^[193]^B2b

Tuberculosis screening

Tuberculosis (TB) assessment should be risk-based and incorporate exposure history, symptoms, and chest imaging. A single-center IEI cohort used tuberculin skin testing (TST), repeating the test after 1–4 weeks when the initial induration measured 0–4 mm, together with chest radiography and, when available, computed tomography. ^[248]^C These findings support a structured approach in which a negative or low-response TST is interpreted cautiously in IEI and does not replace clinical assessment or imaging when exposure, symptoms, or radiographic concern is present. ^[248]^C

Gastric and other malignancy surveillance

CVID is associated with clinically important malignancy risk, including B-cell lymphoma and gastric cancer. ^[290]^C In a five-year prospective study of 512 CVID patients, 400 upper gastrointestinal endoscopies were performed; histology identified precancerous gastric lesions in approximately one-third of patients. ^[290]^C Endoscopic surveillance should therefore be individualized according to prior findings, gastrointestinal symptoms, family history, and local specialist practice, with particular attention to patients with previously detected precancerous lesions. ^[290]^C

Malignancy surveillance should extend beyond the stomach and be guided by phenotype, age, family history, examination findings, and disease-specific risks. A retrospective adult IEI study identified neoplasia in 40 of 355 patients, with a median age of 51.58 years, illustrating the need for longitudinal monitoring for both hematologic and solid tumors. ^[97]^C4 Separate population-level work specifically evaluated head and neck cancer risk in primary immunodeficiency, indicating that head and neck symptoms and examination findings should not be overlooked during routine follow-up. ^[108]^B3b

Autoimmune and immune-dysregulation monitoring

CVID surveillance should include periodic review for autoimmune cytopenias and other immune-dysregulation complications. In a prospective cohort of 47 adult CVID patients with autoimmune thrombocytopenia, 25.5% experienced autoimmune thrombocytopenia episodes during 64 months of follow-up. ^[234]^B2b Platelet counts and bleeding symptoms should therefore be assessed promptly when clinically indicated, particularly in patients with previous cytopenia. ^[234]^B2b

Diagnostic and individualized surveillance planning

Because CVID is genetically and phenotypically heterogeneous, surveillance should be adapted to complications, age at onset, family history, autoimmunity, lymphoproliferation, enteropathy, and laboratory phenotype. ^[32]^C4^[232]^C4 Targeted next-generation sequencing has been applied particularly in patients with early onset, autoimmunity, low memory B-cell numbers, family history, or lymphoproliferation, supporting genetic evaluation when these features are present. ^[232]^C4 The overall prevention plan should be reviewed longitudinally and coordinated with immunology, respiratory, gastroenterology, oncology, and infectious-disease specialists according to the patient’s evolving risks. ^[32]^C4^[97]^C4^[290]^C

Evidence-informed surveillance priorities

Domain	Surveillance focus	Supporting evidence
Respiratory infection	Breakthrough infections, pneumonia, IgRT effectiveness and tolerability	^[254]^[299]^C
COVID-19	Vaccination and boosters; do not rely on antibody results alone; assess persistent symptoms	^[65]^B2b^[100]^B2b^[173]^C4^[193]^B2b^[241]^C^[267]^C^[268]^[271]
Tuberculosis	Exposure history, symptoms, TST with repeat testing when appropriate, chest imaging	^[248]^C
Gastric disease	Individualized upper-GI endoscopic surveillance and histologic assessment of precancerous lesions	^[290]^C
Malignancy	Clinical monitoring for hematologic, gastric, head and neck, and other cancers	^[97]^C4^[108]^B3b^[290]^C
Autoimmunity	Platelet count and bleeding assessment when thrombocytopenia is suspected or previously documented	^[234]^B2b

References

[1]
Unger S, Seidl M, van Schouwenburg P et al.. “The TH1 phenotype of follicular helper T cells indicates an IFN-γ-associated immune dysregulation in patients with CD21low common variable immunodeficiency.” The Journal of allergy and clinical immunology (2017). PMID: 28554560 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Hypersensitivity Mechanism Type
[2]
Jamee M, Zaki-Dizaji M, Lo B et al.. “Clinical, Immunological, and Genetic Features in Patients with Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) and IPEX-like Syndrome.” The journal of allergy and clinical immunology. In practice (2020). PMID: 32428713 ↗
L2SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Prognosis & Natural History
[3]
DiGiacomo DV, Roelstraete B, Lebwohl B et al.. “Predominantly antibody deficiency and the association with celiac disease in Sweden: A nationwide case-control study.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024). PMID: 38331244 ↗
L3CASE_CONTROLCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors
[4]
Kaplan B, Kopyltsova Y, Khokhar A et al.. “Rituximab and immune deficiency: case series and review of the literature.” The journal of allergy and clinical immunology. In practice (2014). PMID: 25213054 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[5]
Fedor ME, Rubinstein A. “Effects of long-term low-dose corticosteroid therapy on humoral immunity.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2006). PMID: 16892792 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Acute Management & Anaphylaxis Pathway
[6]
Schwab C, Gabrysch A, Olbrich P et al.. “Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.” The Journal of allergy and clinical immunology (2018). PMID: 29729943 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Complications, Comorbidities & Iatrogenic Risks
[7]
Magerus A, Rensing-Ehl A, Rao VK et al.. “Autoimmune lymphoproliferative immunodeficiencies (ALPIDs): A proposed approach to redefining ALPS and other lymphoproliferative immune disorders.” The Journal of allergy and clinical immunology (2023). PMID: 37977527 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[8]
Lorenzini T, Fliegauf M, Klammer N et al.. “Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.” The Journal of allergy and clinical immunology (2020). PMID: 32278790 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[9]
Jørgensen SF, Braadland PR, Ueland T et al.. “Tryptophan-kynurenine metabolites associate with inflammation and immunologic phenotypes in common variable immunodeficiency.” The Journal of allergy and clinical immunology (2025). PMID: 40378971 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Complications, Comorbidities & Iatrogenic Risks
[10]
Chinen J, Notarangelo LD, Shearer WT. “Advances in basic and clinical immunology in 2014.” The Journal of allergy and clinical immunology (2015). PMID: 25956014 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History, Prevention, Screening & Surveillance
[11]
Tuijnenburg P, Lango Allen H, Burns SO et al.. “Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans.” The Journal of allergy and clinical immunology (2018). PMID: 29477724 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[12]
Friedmann D, Payne KJ, Cousin V et al.. “Expansion of a distinct cytotoxic CD4 TFH-cell cluster in lymph nodes of patients with complicated common variable immunodeficiency.” The Journal of allergy and clinical immunology (2025). PMID: 41314478 ↗
L3OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type
[13]
Agondi RC, Barros MT, Rizzo LV et al.. “Allergic asthma in patients with common variable immunodeficiency.” Allergy (2009). PMID: 19839975 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[14]
DiGiacomo DV, Roelstraete B, Hammarström L et al.. “Predominant Antibody Deficiency and Risk of Microscopic Colitis: a Nationwide Case-Control Study in Sweden.” Journal of clinical immunology (2023). PMID: 37162615 ↗
L3CASE_CONTROLCited in: Definition, Classification & Hypersensitivity Mechanism Type
[15]
Seidel MG, Kindle G, Gathmann B et al.. “The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity.” The journal of allergy and clinical immunology. In practice (2019). PMID: 30776527 ↗
L5OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[16]
Bez P, Smits B, Geier C et al.. “Uncovering Risk Factors of Premature Mortality in Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40090481 ↗
L3OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[17]
Ameratunga R, Edwards ESJ, Lehnert K et al.. “The Rapidly Expanding Genetic Spectrum of Common Variable Immunodeficiency-Like Disorders.” The journal of allergy and clinical immunology. In practice (2023). PMID: 36796510 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[18]
Filion CA, Taylor-Black S, Maglione PJ et al.. “Differentiation of Common Variable Immunodeficiency From IgG Deficiency.” The journal of allergy and clinical immunology. In practice (2018). PMID: 30557717 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks
[19]
Elmoursi A, DiGiacomo DV, Farmer JR et al.. “Hepatic Manifestations in Common Variable Immunodeficiency Associated With Mortality and Worse Hospital Outcomes in Nationwide Analysis Using National Readmission Database.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40998257 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks
[20]
Agress A, Oprea Y, Roy S et al.. “The Association Between Malignancy, Immunodeficiency, and Atopy in IgE-Deficient Patients.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37863316 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors
[21]
Ogershok PR, Hogan MB, Welch JE et al.. “Spectrum of illness in pediatric common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2006). PMID: 17165275 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Special Populations & Pregnancy
[22]
Ariue B, Patel NC, Bellanti JA. “Lessons from the American College of Allergy, Asthma and Immunology inborn errors of immunity survey: Advancing diagnostic and therapeutic strategies for the practicing allergist-immunologist.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 41057108 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[23]
Lee WI, Huang JL, Kuo ML et al.. “Analysis of genetic defects in patients with the common variable immunodeficiency phenotype in a single Taiwanese tertiary care hospital.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 18051214 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type
[24]
Ombrello MJ, Remmers EF, Sun G et al.. “Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions.” The New England journal of medicine (2012). PMID: 22236196 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[25]
Park MA, Li JT, Hagan JB et al.. “Common variable immunodeficiency: a new look at an old disease.” Lancet (London, England) (2008). PMID: 18692715 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[26]
Urban B, Batlle-Masó L, Perurena-Prieto J et al.. “Heterozygous Predicted Loss-of-function Variants of TRAF3 in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2024). PMID: 39579173 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[27]
Drabe CH, Laustsen MM, Marquart HV et al.. “Genetics in a Danish Common Variable Immunodeficiency Cohort.” Journal of clinical immunology (2025). PMID: 40455168 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[28]
Thoré P, Jaïs X, Savale L et al.. “Pulmonary Hypertension in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2021). PMID: 34110542 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[29]
Bargir UA, Setia P, Desai M et al.. “Common Variable Immunodeficiency Disorder: A Decade of Insights from a Cohort of 150 Patients in India and the Use of Machine Learning Algorithms to Predict Severity.” Journal of clinical immunology (2025). PMID: 40856873 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Special Populations & Pregnancy
[30]
Thouvenel CD, Tipton CM, Yamazaki Y et al.. “Hypomorphic RAG2 Deficiency Promotes Selection of Self-Reactive B Cells.” Journal of clinical immunology (2025). PMID: 39812873 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[31]
van Stigt AC, von der Thüsen JH, Mustafa DAM et al.. “Granulomas in Common Variable Immunodeficiency Display Different Histopathological Features Compared to Other Granulomatous Diseases.” Journal of clinical immunology (2024). PMID: 39373788 ↗
L3OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[32]
Fortier JC, Haltigan E, Cavero-Chavez V et al.. “Clinical and Phenotypic Characterization of Common Variable Immunodeficiency Diagnosed in Younger and Older Adults.” Journal of clinical immunology (2022). PMID: 35588029 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[33]
Hägele P, Staus P, Scheible R et al.. “Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study.” The Lancet. Haematology (2024). PMID: 38302222 ↗
L2COHORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification
[34]
Llobet MP, Soler-Palacin P, Detkova D et al.. “Common variable immunodeficiency: 20-yr experience at a single centre.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2008). PMID: 18798799 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History, Prevention, Screening & Surveillance
[35]
Perez-Perez D, Santos-Argumedo L, Rodriguez-Alba JC et al.. “Analysis of LRBA pathogenic variants and the association with functional protein domains and clinical presentation.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024). PMID: 38923448 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification
[36]
Costagliola G, De Marco E, Amato L et al.. “Sponge-like sonographic pattern of the spleen in immune dysregulation disorders.” Frontiers in immunology (2026). PMID: 42375368 ↗
L3CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[37]
Endo Y, Koga T, Kurushima S et al.. “Case Report: Novel IRF2BP2 variant in a Japanese patient with impaired B-cell differentiation, Th1 polarization, and systemic immune dysregulation.” Frontiers in immunology (2025). PMID: 41246352 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation
[38]
Sormani J, Belot A, Nove-Josserand R et al.. “A New Variant in CTLA4 Highlights the Heterogeneous Phenotype of CTLA4 Haploinsufficiency.” Journal of clinical immunology (2025). PMID: 41219619 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[39]
Nishikawa T, Tomomasa D, Hijikata A et al.. “Case Report: CD40LG Arg203Ile variant underlies atypical phenotype of X-linked hyper IgM syndrome.” Frontiers in immunology (2025). PMID: 40391217 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[40]
González-Torbay A, Reche-Yebra K, Clemente-Bernal Á et al.. “Functional insights of an uncommon hypomorphic variant in IL2RG as a monogenic cause of CVID-like disease with antibody deficiency and T CD4 lymphopenia.” Frontiers in immunology (2025). PMID: 40170851 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism
[41]
Ak B, Parıltay E, Gümüşburun R et al.. “Uniparental Disomy of Chromosome 4: A Case of Whole Chromosome UPD Presenting with LRBA Deficiency.” Journal of clinical immunology (2024). PMID: 39289195 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism
[42]
Le Coz C, Bengsch B, Khanna C et al.. “Common variable immunodeficiency-associated endotoxemia promotes early commitment to the T follicular lineage.” The Journal of allergy and clinical immunology (2019). PMID: 31445098 ↗
L4TRIAL_NONRANDOMCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[43]
von Spee-Mayer C, Echternach C, Agarwal P et al.. “Abatacept Use Is Associated with Steroid Dose Reduction and Improvement in Fatigue and CD4-Dysregulation in CVID Patients with Interstitial Lung Disease.” The journal of allergy and clinical immunology. In practice (2020). PMID: 33223097 ↗
L2TRIAL_NONRANDOMCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway
[44]
Lang A, Agharahimi A, Vogel TP et al.. “From CVID to PIRD: Genetic Testing Leading to Signal Transducer and Activator of Transcription 3 Gain-of-Function Diagnosis and Directed Therapy.” The journal of allergy and clinical immunology. In practice (2026). PMID: 41999916 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[45]
Agarwal S, Cunningham-Rundles C. “Thymoma and immunodeficiency (Good syndrome): a report of 2 unusual cases and review of the literature.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17304889 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[46]
Narula S, LaRosa DF, Kamoun M et al.. “Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17521034 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation
[47]
Udemgba C, Pillay B, Shafer S et al.. “IRF2BP2 deficiency: An important form of common variable immunodeficiency with inflammation.” The Journal of allergy and clinical immunology (2025). PMID: 40090425 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[48]
Chinen J, Cowan MJ. “Advances and highlights in primary immunodeficiencies in 2017.” The Journal of allergy and clinical immunology (2018). PMID: 30170128 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[49]
Abyazi ML, Bell KA, Gyimesi G et al.. “Convergence of cytokine dysregulation and antibody deficiency in common variable immunodeficiency with inflammatory complications.” The Journal of allergy and clinical immunology (2021). PMID: 34146579 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
[50]
Kaarbø M, Yang M, Hov JR et al.. “Duodenal inflammation in common variable immunodeficiency has altered transcriptional response to viruses.” The Journal of allergy and clinical immunology (2022). PMID: 36220400 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism
[51]
Le Coz C, Trofa M, Butler DL et al.. “The common variable immunodeficiency IgM repertoire narrowly recognizes erythrocyte and platelet glycans.” The Journal of allergy and clinical immunology (2024). PMID: 38692308 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism
[52]
Ho HE, Radigan L, Qi J et al.. “Bruton tyrosine kinase modulates systemic immune activation to bacterial translocation in primary antibody deficiencies.” The Journal of allergy and clinical immunology (2025). PMID: 41033468 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism
[53]
Boast B, Goel S, González-Granado LI et al.. “TCF3 haploinsufficiency defined by immune, clinical, gene-dosage, and murine studies.” The Journal of allergy and clinical immunology (2023). PMID: 37277074 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[54]
Urdea D, Mereuta DV, Iorga RE et al.. “Concurrent hereditary angioedema type I and common variable immunodeficiency presenting as suspected antibiotic hypersensitivity: Case report and literature discussion.” The World Allergy Organization journal (2026). PMID: 42221876 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[55]
Friedmann D, Goldacker S, Peter HH et al.. “Preserved Cellular Immunity Upon Influenza Vaccination in Most Patients with Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2020). PMID: 32330665 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[56]
Schussler E, Beasley MB, Maglione PJ. “Lung Disease in Primary Antibody Deficiencies.” The journal of allergy and clinical immunology. In practice (2016). PMID: 27836055 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[57]
Yin J, Hayes KM, Ong MS et al.. “Common Variable Immunodeficiency Clinical Manifestations Are Shaped by Presence and Type of Heterozygous NFKB1 Variants.” The journal of allergy and clinical immunology. In practice (2024). PMID: 39672378 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
[58]
Ameratunga R, Longhurst H, Steele R et al.. “Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19.” The journal of allergy and clinical immunology. In practice (2021). PMID: 34182162 ↗
L5OTHERCited in: Pathophysiology & Immune Mechanism, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[59]
Milota T, Smetanova J, Skotnicova A et al.. “Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency.” The journal of allergy and clinical immunology. In practice (2022). PMID: 36379409 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[60]
van de Ven A, Mader I, Wolff D et al.. “Structural Noninfectious Manifestations of the Central Nervous System in Common Variable Immunodeficiency Disorders.” The journal of allergy and clinical immunology. In practice (2019). PMID: 31857261 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism
[61]
Agarwal S, Cunningham-Rundles C. “Autoimmunity in common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2019). PMID: 31349011 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[62]
Durkee-Shock JR, Keller MD. “Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2022). PMID: 35718282 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prevention, Screening & Surveillance
[63]
Ballow M. “Managing comorbid complications in patients with common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2013). PMID: 24267402 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Complications, Comorbidities & Iatrogenic Risks
[64]
Maglione PJ, Overbey JR, Radigan L et al.. “Pulmonary radiologic findings in common variable immunodeficiency: clinical and immunological correlations.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2014). PMID: 24880814 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[65]
Rosenthal JA, Papa MP, Sanz M et al.. “Antibody and T-cell responses to coronavirus disease 2019 vaccination in common variable immunodeficiency and specific antibody deficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2023). PMID: 36736722 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[66]
Hashiguchi S, Tomomasa D, Nishikawa T et al.. “18q Deletion Syndrome Presenting with Late-Onset Combined Immunodeficiency.” Journal of clinical immunology (2024). PMID: 38896123 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism
[67]
Vossen MG, Kartnig F, Mrak D et al.. “Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency : A prospective controlled open-label trial.” Wiener klinische Wochenschrift (2024). PMID: 39446203 ↗
L2RCTCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway
[68]
Yel L. “Selective IgA deficiency.” Journal of clinical immunology (2010). PMID: 20101521 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway
[69]
Cunningham-Rundles C. “Autoimmune manifestations in common variable immunodeficiency.” Journal of clinical immunology (2008). PMID: 18322785 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism
[70]
Strohmeier V, Andrieux G, Unger S et al.. “Interferon-Driven Immune Dysregulation in Common Variable Immunodeficiency-Associated Villous Atrophy and Norovirus Infection.” Journal of clinical immunology (2022). PMID: 36282455 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification
[71]
Sekinaka Y, Mitsuiki N, Imai K et al.. “Common Variable Immunodeficiency Caused by FANC Mutations.” Journal of clinical immunology (2017). PMID: 28493158 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[72]
Arroyo-Sánchez D, Cabrera-Marante O, Laguna-Goya R et al.. “Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.” Journal of clinical immunology (2021). PMID: 34787773 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[73]
Rodríguez-Cortez VC, Del Pino-Molina L, Rodríguez-Ubreva J et al.. “Dissecting Epigenetic Dysregulation of Primary Antibody Deficiencies.” Journal of clinical immunology (2016). PMID: 26984849 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism
[74]
Hel Z, Huijbregts RP, Xu J et al.. “Altered serum cytokine signature in common variable immunodeficiency.” Journal of clinical immunology (2014). PMID: 25246148 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism
[75]
Yang M, Kaarbø M, Myhre V et al.. “Altered Genome-Wide DNA Methylation in the Duodenum of Common Variable Immunodeficiency Patients.” Journal of clinical immunology (2024). PMID: 38780872 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism
[76]
Soltani M, Rezaei M, Fekrvand S et al.. “Role of rare immune cells in common variable immunodeficiency.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2022). PMID: 34937129 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[77]
Yong PL, Orange JS, Sullivan KE. “Pediatric common variable immunodeficiency: immunologic and phenotypic associations with switched memory B cells.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2010). PMID: 20337966 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[78]
Lenti MV, Savioli J, Achilli G et al.. “Autoimmune diseases associated with common variable immune deficiency.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020). PMID: 33236426 ↗
L5OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks
[79]
Kutukculer N, Gulez N. “The outcome of patients with unclassified hypogammaglobulinemia in early childhood.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19196447 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[80]
Tegtmeyer D, Seidl M, Gerner P et al.. “Inflammatory bowel disease caused by primary immunodeficiencies-Clinical presentations, review of literature, and proposal of a rational diagnostic algorithm.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2017). PMID: 28513998 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[81]
Zeng W, Feng X, Liang B et al.. “Good syndrome presenting with multiple pulmonary infections: a case report involving metagenomic sequencing diagnosis.” Frontiers in medicine (2025). PMID: 40904363 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
[82]
Consolini R, Maestrini G, Abu-Rumeileh S et al.. “The Intertwining Between Arthritis and Inborn Errors of Immunity.” Journal of clinical medicine (2026). PMID: 42123030 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism
[83]
Yang M, Kaarbø M, Myhre V et al.. “Distinct Proteomic and Transcriptomic Profiles in T-cells and Monocytes in Patients with Common Variable Immunodeficiency: an Exploratory Study.” Journal of clinical immunology (2026). PMID: 41991796 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
[84]
Comans SET, Sprenkeler EGG, Koenen MH et al.. “Familial patterns of immune dysregulation in CVID: insights from B- and T-cell phenotyping and antibody profiling.” Frontiers in immunology (2026). PMID: 41909677 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Prevention, Screening & Surveillance
[85]
Briassouli E, Marinakis N, Spoulou V et al.. “IL2RG-related immunodeficiencies: from SCID to atypical presentations.” Frontiers in immunology (2026). PMID: 41909668 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Prognosis & Natural History
[86]
Fekrvand S, Abolhassani H, Esfahani ZH et al.. “Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis.” Journal of clinical immunology (2024). PMID: 39466473 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
[87]
Egg D, Rump IC, Mitsuiki N et al.. “Therapeutic options for CTLA-4 insufficiency.” The Journal of allergy and clinical immunology (2021). PMID: 34111452 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[88]
Torres-Valle A, Neirinck J, Silva SL et al.. “Immunologic biomarkers of noninfectious complications and overall survival in common variable immunodeficiency.” The Journal of allergy and clinical immunology (2025). PMID: 41176068 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[89]
Gray PE, David C. “Inborn Errors of Immunity and Autoimmune Disease.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37119983 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
[90]
Jolles S. “The variable in common variable immunodeficiency: a disease of complex phenotypes.” The journal of allergy and clinical immunology. In practice (2013). PMID: 24565700 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks
[91]
Cunningham-Rundles C. “Current concepts: Common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 41274495 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
[92]
Moazzami B, Mohayeji Nasrabadi MA, Abolhassani H et al.. “Comprehensive assessment of respiratory complications in patients with common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2020). PMID: 32007567 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[93]
Ferastraoaru D, Gross R, Rosenstreich D. “Increased malignancy incidence in IgE deficient patients not due to concomitant Common Variable Immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2017). PMID: 28778662 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[94]
De Renzis C, Gambier RF, Gigante A et al.. “Chronic Kidney Disease in Common Variable Immunodeficiency: a Multicenter Study.” Journal of clinical immunology (2025). PMID: 40407942 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[95]
van der Poorten DK, McLeod D, Ahlenstiel G et al.. “Gastric Cancer Screening in Common Variable Immunodeficiency.” Journal of clinical immunology (2018). PMID: 30219982 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prevention, Screening & Surveillance
[96]
Garcia-Prat M, Batlle-Masó L, Parra-Martínez A et al.. “Role of Skewed X-Chromosome Inactivation in Common Variable Immunodeficiency.” Journal of clinical immunology (2024). PMID: 38265673 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[97]
Gumusburun R, Yıldırım O, Karakoc M et al.. “Malignancy in Adults with Inborn Errors of Immunity: A Retrospective Single-Center Study.” Journal of clinical immunology (2025). PMID: 40993321 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[98]
Punj M, Neshat SS, Mateus AYL et al.. “Assessment of Sleep Disorders in Patients with CVID.” Journal of clinical immunology (2024). PMID: 38676767 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
[99]
Sperlich JM, Grimbacher B, Soetedjo V et al.. “Predictive Factors for and Complications of Bronchiectasis in Common Variable Immunodeficiency Disorders.” Journal of clinical immunology (2022). PMID: 35015197 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
[100]
Villa A, Milito C, Deiana CM et al.. “High Prevalence of Long COVID in Common Variable Immunodeficiency: An Italian Multicentric Study.” Journal of clinical immunology (2024). PMID: 38319477 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[101]
Puzenat DT, Cheminant M, Dannaoui E et al.. “Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).” The Journal of infectious diseases (2026). PMID: 42378670 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
[102]
Miranda-Bautista J, Martínez-Lozano H, Di Natale M et al.. “The Prognostic Impact of Enteropathy and Liver Disease in Common Variable Immunodeficiency: A Retrospective Cohort Study.” Clinical and translational gastroenterology (2026). PMID: 41324469 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[103]
Dogru D, Dogru Y, Atschekzei F et al.. “Reappraisal of IgG subclass deficiencies: a retrospective comparative cohort study.” Frontiers in immunology (2025). PMID: 40313941 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors
[104]
Cekic S, Metin A, Aytekin C et al.. “The evaluation of malignancies in Turkish primary immunodeficiency patients; a multicenter study.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020). PMID: 32060950 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[105]
Baris S, Ozen A, Ercan H et al.. “Osteoporosis: an ignored complication of CVID.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2011). PMID: 21645119 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification
[106]
Azizi G, Tavakol M, Yazdani R et al.. “Autoimmune manifestations among 461 patients with monogenic inborn errors of immunity.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 33774840 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
[107]
Zhang J, Cai H, Zhu T et al.. “Clinical, genetic, and functional characterization of novel NFKB1 variants in Chinese patients with primary immunodeficiency.” Clinical and experimental immunology (2026). PMID: 42252100 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks
[108]
Wenger TA, Collet C, West J et al.. “Rates and Outcomes of Head and Neck Cancer Among Patients With Primary Immunodeficiency Disorders.” Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2026). PMID: 42171009 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[109]
Martinez T, Grand Z, Garcia S et al.. “A global perspective on autoimmunity and immunodeficiency: exploring geoepidemiology trends.” Current opinion in immunology (2026). PMID: 41980333 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[110]
Romberg N, Le Coz C, Glauzy S et al.. “Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses.” The Journal of allergy and clinical immunology (2018). PMID: 29935219 ↗
L3TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[111]
Bonilla FA, Barlan I, Chapel H et al.. “International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.” The journal of allergy and clinical immunology. In practice (2015). PMID: 26563668 ↗
L1OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[112]
Mayampurath A, Ajith A, Anderson-Smits C et al.. “Early Diagnosis of Primary Immunodeficiency Disease Using Clinical Data and Machine Learning.” The journal of allergy and clinical immunology. In practice (2022). PMID: 36108921 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[113]
DeVries AS, Harper J, Murray A et al.. “Vaccine-derived poliomyelitis 12 years after infection in Minnesota.” The New England journal of medicine (2011). PMID: 21675890 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[114]
Lee TK, Gereige JD, Maglione PJ. “State-of-the-art diagnostic evaluation of common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2021). PMID: 33716149 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[115]
Izadi N, Knight V, Strand M et al.. “An enzyme-linked immunospot assay to evaluate Pneumovax response when on intravenous immunoglobulin.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2021). PMID: 34391898 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[116]
Hartono S, Motosue MS, Khan S et al.. “Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2017). PMID: 28254202 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[117]
Kuehn HS, Boisson B, Cunningham-Rundles C et al.. “Loss of B Cells in Patients with Heterozygous Mutations in IKAROS.” The New England journal of medicine (2016). PMID: 26981933 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prevention, Screening & Surveillance
[118]
Touw CM, van de Ven AA, de Jong PA et al.. “Detection of pulmonary complications in common variable immunodeficiency.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19912551 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[119]
Reznik EV, Iarovoi MD, Romanova TS et al.. “Prolonged Infections and Inflammatory Diseases in Common Variable Immune Deficiency as a Cause of AA Amyloidosis.” Journal of clinical medicine (2026). PMID: 42278892 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[120]
Hbibi M, Elamine A, Benhsaien I et al.. “Case Report: Different faces of LRBA deficiency in five Moroccan families.” Frontiers in immunology (2026). PMID: 42148132 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[121]
Varenne F, Siegfried-Vergnon A, Lhomme S et al.. “JC Virus-Related Retinopathy.” JAMA ophthalmology (2025). PMID: 40674067 ↗
L4CASE_REPORTCited in: Clinical Presentation, Acute Management & Anaphylaxis Pathway, Prognosis & Natural History
[122]
Schwitzguébel AJ, Jandus P, Lacroix JS et al.. “Immunoglobulin deficiency in patients with chronic rhinosinusitis: Systematic review of the literature and meta-analysis.” The Journal of allergy and clinical immunology (2015). PMID: 26329513 ↗
L1SR_OBSCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[123]
Jerschow E, De Vos GS, Hudes G et al.. “A case of common variable immunodeficiency syndrome associated with Takayasu arteritis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17304891 ↗
L4CASE_REPORTCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[124]
Renz H. “Advances in in vitro diagnostics in allergy, asthma, and immunology in 2012.” The Journal of allergy and clinical immunology (2013). PMID: 24139605 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prevention, Screening & Surveillance
[125]
Sperlich JM, Grimbacher B, Workman S et al.. “Respiratory Infections and Antibiotic Usage in Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2017). PMID: 28734862 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[126]
Hurst JR, Verma N, Lowe D et al.. “British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders.” The journal of allergy and clinical immunology. In practice (2017). PMID: 28351785 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks
[127]
Maglione PJ, Ko HM, Tokuyama M et al.. “Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.” The journal of allergy and clinical immunology. In practice (2019). PMID: 31430592 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
[128]
Maglione PJ, Overbey JR, Cunningham-Rundles C. “Progression of Common Variable Immunodeficiency Interstitial Lung Disease Accompanies Distinct Pulmonary and Laboratory Findings.” The journal of allergy and clinical immunology. In practice (2015). PMID: 26372540 ↗
L2OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[129]
Roa-Bautista A, Brown LK, Tadros S et al.. “Clinical Features, Immunological Characteristics, and Treatment Outcomes of Campylobacter spp. Infections in Patients With Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37406804 ↗
L2OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[130]
Busse PJ, Farzan S, Cunningham-Rundles C. “Pulmonary complications of common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17225714 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[131]
Deyà-Martínez A, Esteve-Solé A, Vélez-Tirado N et al.. “Sirolimus as an alternative treatment in patients with granulomatous-lymphocytic lung disease and humoral immunodeficiency with impaired regulatory T cells.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2018). PMID: 29532571 ↗
L4CASE_REPORTCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[132]
Lopes-da-Silva S, Rizzo LV. “Autoimmunity in common variable immunodeficiency.” Journal of clinical immunology (2008). PMID: 18443901 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History, Prevention, Screening & Surveillance
[133]
Shapiro RS, Wasserman RL, Bonagura V et al.. “Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.” Journal of clinical immunology (2014). PMID: 24477950 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[134]
Hoernes M, Seger R, Reichenbach J. “Modern management of primary B-cell immunodeficiencies.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2011). PMID: 22122788 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
[135]
Palmeira P, Costa-Carvalho BT, Arslanian C et al.. “Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19220771 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Special Populations & Pregnancy
[136]
Stojanovic M, Stojkovic-Lalosevic M, Stankovic S et al.. “Non-invasive assessment of hepatic involvement in common variable immunodeficiency and agammaglobulinemia using enhanced liver fibrosis score and shearwave elastography.” Frontiers in immunology (2026). PMID: 42421971 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[137]
Elmoursi A, Charlier C, Cunningham-Rundles C et al.. “Insights into Clinical Challenges and Management of Primary and Secondary Antibody Deficiency in Pregnancy.” The journal of allergy and clinical immunology. In practice (2026). PMID: 42250902 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[138]
Matson EM, Ware MS, Feng F et al.. “Coexistent alterations of BAFF and B-cell phenotypes in complicated CVID course.” The Journal of allergy and clinical immunology (2026). PMID: 42219089 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[139]
Smits B, Goldacker S, Seneviratne S et al.. “The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease.” The Journal of allergy and clinical immunology (2022). PMID: 36587851 ↗
L4RCTCited in: Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[140]
Gardulf A, Abolhassani H, Gustafson R et al.. “Predictive markers for humoral influenza vaccine response in patients with common variable immunodeficiency.” The Journal of allergy and clinical immunology (2018). PMID: 29678747 ↗
L4TRIAL_NONRANDOMCited in: Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[141]
Chase NM, Verbsky JW, Hintermeyer MK et al.. “Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID).” Journal of clinical immunology (2012). PMID: 22930256 ↗
L4RCTCited in: Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[142]
Bergman P, Wullimann D, Gao Y et al.. “Elevated CD21low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2022). PMID: 35290571 ↗
L2TRIAL_NONRANDOMCited in: Severity, Grading & Risk Stratification
[143]
Mandola AB, Sharfe N, Nagdi Z et al.. “Combined immunodeficiency caused by a novel homozygous NFKB1 mutation.” The Journal of allergy and clinical immunology (2020). PMID: 32980423 ↗
L4CASE_REPORTCited in: Severity, Grading & Risk Stratification
[144]
Abraham RS, Marshall JM, Kuehn HS et al.. “Severe SARS-CoV-2 disease in the context of a NF-κB2 loss-of-function pathogenic variant.” The Journal of allergy and clinical immunology (2020). PMID: 33007327 ↗
L4CASE_REPORTCited in: Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History
[145]
Materne E, Zhou B, DiGiacomo D et al.. “Renal complications in patients with predominantly antibody deficiency in the United States Immune Deficiency Network (USIDNET).” The Journal of allergy and clinical immunology (2024). PMID: 38555979 ↗
L2OTHERCited in: Severity, Grading & Risk Stratification
[146]
Hennig C, Ilginus C, Boztug K et al.. “High-content cytometry and transcriptomic biomarker profiling of human B-cell activation.” The Journal of allergy and clinical immunology (2013). PMID: 24012209 ↗
L5OTHERCited in: Severity, Grading & Risk Stratification
[147]
Bintalib HM, van de Ven AAJM, Rojas-Reyes MX et al.. “Clinical Practice Guideline for the diagnosis of Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD) in patients with Common Variable Immunodeficiency Disorders (CVID) - an ERS Clinical Research Collaboration.” The European respiratory journal (2026). PMID: 42350065 ↗
L1GUIDELINECited in: Severity, Grading & Risk Stratification, Prognosis & Natural History
[148]
Smits BM, Boland SL, Hol ME et al.. “Pulmonary Computed Tomography Screening Frequency in Primary Antibody Deficiency.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38182096 ↗
L2OTHERCited in: Severity, Grading & Risk Stratification
[149]
Yazdani R, Abolhassani H, Kiaee F et al.. “Comparison of Common Monogenic Defects in a Large Predominantly Antibody Deficiency Cohort.” The journal of allergy and clinical immunology. In practice (2018). PMID: 30240888 ↗
L2OTHERCited in: Severity, Grading & Risk Stratification, Prognosis & Natural History
[150]
D'Silva SJ, Patrie J, Noonan E et al.. “Undetectable IgE association with noninfectious complications of common variable immune deficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 41390140 ↗
L2OTHERCited in: Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks
[151]
Boztug H, Hirschmugl T, Holter W et al.. “NF-κB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation.” Journal of clinical immunology (2016). PMID: 27338827 ↗
L4CASE_REPORTCited in: Severity, Grading & Risk Stratification
[152]
Slade CA, McLean C, Scerri T et al.. “Fatal Enteroviral Encephalitis in a Patient with Common Variable Immunodeficiency Harbouring a Novel Mutation in NFKB2.” Journal of clinical immunology (2019). PMID: 30927119 ↗
L4CASE_REPORTCited in: Severity, Grading & Risk Stratification
[153]
Karafotias I, Martini H, Lee CV et al.. “CXCL13 as a Biomarker of Complex Common Variable Immunodeficiency.” Journal of clinical immunology (2025). PMID: 41288852 ↗
L3OTHERCited in: Severity, Grading & Risk Stratification
[154]
Bergmans B, Fontane Pennock-Janssen L, van Puijenbroek E et al.. “Exploring the Pathogens in Primary Predominantly Antibody Deficiencies of Unknown Genetic Origin.” Journal of clinical immunology (2025). PMID: 41384995 ↗
L2OTHERCited in: Severity, Grading & Risk Stratification, Prognosis & Natural History
[155]
Katzenstein TL, Rasmussen LD, Drabe CH et al.. “Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: A Danish nationwide cohort study.” Frontiers in immunology (2022). PMID: 36211430 ↗
L2COHORTCited in: Severity, Grading & Risk Stratification
[156]
Danieli MG, Verga JU, Mezzanotte C et al.. “Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.” Frontiers in immunology (2022). PMID: 35111165 ↗
L4COHORTCited in: Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway
[157]
Russo R, Andolfo I, Lasorsa VA et al.. “The TNFRSF13C H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern Italy.” Genes (2021). PMID: 34201032 ↗
L3COHORTCited in: Severity, Grading & Risk Stratification
[158]
van der Heijden J, Geissler J, van Mirre E et al.. “A novel splice variant of FcγRIIa: a risk factor for anaphylaxis in patients with hypogammaglobulinemia.” The Journal of allergy and clinical immunology (2013). PMID: 23545275 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway
[159]
Arora R, Newton TC, Nelson MR. “Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand disease.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17941286 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Special Populations & Pregnancy
[160]
Chinen J, Notarangelo LD, Shearer WT. “Advances in clinical immunology in 2015.” The Journal of allergy and clinical immunology (2016). PMID: 27931534 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[161]
Chinen J, Badran YR, Geha RS et al.. “Advances in basic and clinical immunology in 2016.” The Journal of allergy and clinical immunology (2017). PMID: 28826774 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[162]
Bonilla FA, Geha RS. “2. Update on primary immunodeficiency diseases.” The Journal of allergy and clinical immunology (2006). PMID: 16455342 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[163]
Gathmann B, Mahlaoui N, Gérard L et al.. “Clinical picture and treatment of 2212 patients with common variable immunodeficiency.” The Journal of allergy and clinical immunology (2014). PMID: 24582312 ↗
L2OTHERCited in: Acute Management & Anaphylaxis Pathway
[164]
Wehr C, Gennery AR, Lindemans C et al.. “Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency.” The Journal of allergy and clinical immunology (2015). PMID: 25595268 ↗
L4OTHERCited in: Acute Management & Anaphylaxis Pathway
[165]
Pulvirenti F, Cinetto F, Milito C et al.. “Health-Related Quality of Life in Common Variable Immunodeficiency Italian Patients Switched to Remote Assistance During the COVID-19 Pandemic.” The journal of allergy and clinical immunology. In practice (2020). PMID: 32278865 ↗
L4OTHERCited in: Acute Management & Anaphylaxis Pathway
[166]
Zuzolo J, Zulfiqar MF, Spoelhof B et al.. “Functional testing of humoral immunity in the Prevnar 20 era.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024). PMID: 39681261 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[167]
Lang-Meli J, Fuchs J, Mathé P et al.. “Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.” Journal of clinical immunology (2021). PMID: 34893946 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway
[168]
Ilkjær FV, Johansen IS, Martin-Iguacel R et al.. “Evaluating Drug Prescription Patterns in Undiagnosed Common Variable Immunodeficiency Patients.” Journal of clinical immunology (2023). PMID: 37833619 ↗
L3OTHERCited in: Acute Management & Anaphylaxis Pathway
[169]
Ilkjær FV, Rasmussen LD, Martin-Iguacel R et al.. “How to Identify Common Variable Immunodeficiency Patients Earlier: General Practice Patterns.” Journal of clinical immunology (2019). PMID: 31372799 ↗
L3OTHERCited in: Acute Management & Anaphylaxis Pathway
[170]
Lawrence MG, Palacios-Kibler TV, Workman LJ et al.. “Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID).” Journal of clinical immunology (2018). PMID: 29453744 ↗
L3OTHERCited in: Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[171]
Baloh C, Reddy A, Henson M et al.. “30-Year Review of Pediatric- and Adult-Onset CVID: Clinical Correlates and Prognostic Indicators.” Journal of clinical immunology (2019). PMID: 31377970 ↗
L2REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
[172]
Cagdas D, Halaçlı SO, Tan Ç et al.. “A Spectrum of Clinical Findings from ALPS to CVID: Several Novel LRBA Defects.” Journal of clinical immunology (2019). PMID: 31432443 ↗
L4OTHERCited in: Acute Management & Anaphylaxis Pathway
[173]
Steiner S, Schwarz T, Corman VM et al.. “Impaired B Cell Recall Memory and Reduced Antibody Avidity but Robust T Cell Response in CVID Patients After COVID-19 Vaccination.” Journal of clinical immunology (2023). PMID: 36932291 ↗
L4OTHERCited in: Acute Management & Anaphylaxis Pathway
[174]
Aiello V, Ferrillo M, Marotta N et al.. “Temporomandibular joint arthritis in rheumatic diseases patients: which are the effective rehabilitative approaches for pain relief? A systematic review.” BMC musculoskeletal disorders (2025). PMID: 39966784 ↗
L1SR_OBSCited in: Acute Management & Anaphylaxis Pathway
[175]
Budhipramono A, Sharma R, Wysocki CA et al.. “Therapeutic Plasma Exchange Management for a Pediatric Patient Presenting With Immune Thrombotic Thrombocytopenic Purpura in a Setting of Common Variable Immunodeficiency.” Journal of clinical apheresis (2024). PMID: 39511768 ↗
L4SR_OBSCited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
[176]
Napiórkowska-Baran K, Biliński J, Pujanek M et al.. “Fecal microbiota transplantation in a patient with chronic diarrhea and primary and secondary immunodeficiency (common variable immunodeficiency and splenectomy).” Frontiers in cellular and infection microbiology (2024). PMID: 39403201 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway
[177]
Bermingham WH, Canning B, Wilton T et al.. “Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection.” Frontiers in immunology (2023). PMID: 36936936 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
[178]
Martins B, Miranda J, Pinto MJ et al.. “Common variable immunodeficiency and its inflammatory neurological manifestations: A case report and literature review.” Multiple sclerosis and related disorders (2022). PMID: 35985210 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[179]
Luterbacher F, Bernard F, Baleydier F et al.. “Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT.” Frontiers in immunology (2021). PMID: 35003091 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
[180]
Rezaei N, Hedayat M, Aghamohammadi A et al.. “Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.” The Journal of allergy and clinical immunology (2011). PMID: 21514636 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prevention, Screening & Surveillance
[181]
Mazza JM, Lin SY. “Primary immunodeficiency and recalcitrant chronic sinusitis: a systematic review.” International forum of allergy & rhinology (2016). PMID: 27187624 ↗
L2SR_OBSCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[182]
Arslan S, Poyraz N, Ucar R et al.. “Magnetic Resonance Imaging May Be a Valuable Radiation-Free Technique for Lung Pathologies in Patients with Primary Immunodeficiency.” Journal of clinical immunology (2015). PMID: 26707785 ↗
L4OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[183]
Indinnimeo L, Tancredi G, Barreto M et al.. “Effects of a program of hospital-supervised chest physical therapy on lung function tests in children with chronic respiratory disease: 1-year follow-up.” International journal of immunopathology and pharmacology (2007). PMID: 18179758 ↗
L1RCTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[184]
Pietzsch L, Körholz J, Boschann F et al.. “Hyper-IgE and Carcinoma in CADINS Disease.” Frontiers in immunology (2022). PMID: 35651609 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[185]
Comberiati P, Costagliola G, Carli N et al.. “Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency.” Frontiers in immunology (2019). PMID: 31379880 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[186]
Suyama K, Kawasaki Y, Abe Y et al.. “Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus.” Pediatric nephrology (Berlin, Germany) (2011). PMID: 22207346 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[187]
Zdziarski P, Gamian A. “Lymphoid Interstitial Pneumonia in Common Variable Immune Deficiency - Case Report With Disease Monitoring in Various Therapeutic Options: Pleiotropic Effects of Rituximab Regimens.” Frontiers in pharmacology (2019). PMID: 30713498 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[188]
Yuan S, Hu X, Zhao Y et al.. “Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.” Frontiers in immunology (2020). PMID: 33240259 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[189]
Antachopoulos C, Walsh TJ, Roilides E. “Fungal infections in primary immunodeficiencies.” European journal of pediatrics (2007). PMID: 17551753 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[190]
van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM et al.. “Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.” The Journal of allergy and clinical immunology (2022). PMID: 35421449 ↗
L2RCTCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
[191]
Davé S, Hagan J. “Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administration.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 18219840 ↗
L4CASE_REPORTCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[192]
Morsheimer MM, Rychik J, Forbes L et al.. “Risk Factors and Clinical Significance of Lymphopenia in Survivors of the Fontan Procedure for Single-Ventricle Congenital Cardiac Disease.” The journal of allergy and clinical immunology. In practice (2016). PMID: 26897303 ↗
L2OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[193]
van Leeuwen LPM, Grobben M, GeurtsvanKessel CH et al.. “Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.” Journal of clinical immunology (2023). PMID: 37231290 ↗
L2OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[194]
Giardino G, Milito C, Lougaris V et al.. “The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet).” Journal of clinical immunology (2022). PMID: 35445287 ↗
L4OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Special Populations & Pregnancy
[195]
Beyls E, Duthoo E, Backers L et al.. “Investigating Chromosomal Radiosensitivity in Inborn Errors of Immunity: Insights from DNA Repair Disorders and Beyond.” Journal of clinical immunology (2025). PMID: 39945898 ↗
L3OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[196]
Lin L, Peng X, Chen L et al.. “Case report: novel NFKB2 variant associated with pediatric eosinophilic granulomatosis with polyangiitis (EGPA) in the COVID-19 pandemic.” Pediatric rheumatology online journal (2025). PMID: 40165201 ↗
L4CASE_REPORTCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Special Populations & Pregnancy
[197]
Grammatikos A. “Enteropathy in Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2026). PMID: 41935739 ↗
L5REVIEW_NARRATIVECited in: Complications, Comorbidities & Iatrogenic Risks
[198]
Gregersen S, Aaløkken TM, Mynarek G et al.. “Development of pulmonary abnormalities in patients with common variable immunodeficiency: associations with clinical and immunologic factors.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2010). PMID: 20568383 ↗
L2OTHERCited in: Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[199]
Nguyen JT, Green A, Wilson MR et al.. “Neurologic Complications of Common Variable Immunodeficiency.” Journal of clinical immunology (2016). PMID: 27704236 ↗
L4CASE_REPORTCited in: Complications, Comorbidities & Iatrogenic Risks
[200]
Kralickova P, Kurecova B, Andrys C et al.. “Pregnancy Outcome in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2015). PMID: 26280892 ↗
L2OTHERCited in: Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History, Special Populations & Pregnancy
[201]
Zarezadeh Mehrabadi A, Aghamohamadi N, Abolhassani H et al.. “Comprehensive Assessment of Skin Disorders in Patients with Common Variable Immunodeficiency (CVID).” Journal of clinical immunology (2022). PMID: 35084691 ↗
L4OTHERCited in: Complications, Comorbidities & Iatrogenic Risks
[202]
Elmoursi A, Zhou B, Ong MS et al.. “A Cross-Sectional Study of Health-Related Quality of Life in Patients with Predominantly Antibody Deficiency.” Journal of clinical immunology (2024). PMID: 39110257 ↗
L2OTHERCited in: Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[203]
Cinkavuk E, Akyazi N, Calik E et al.. “An ICF framework analysis of the CVID quality of life questionnaire.” Disability and rehabilitation (2026). PMID: 42080371 ↗
L5OTHERCited in: Complications, Comorbidities & Iatrogenic Risks
[204]
Hayes KM, Boldt K, Schnorr PJ et al.. “Heterozygous NFKB1 variant causes inflammatory dysregulation shaped by broader genetic context in common variable immunodeficiency.” JCI insight (2026). PMID: 41869721 ↗
L5OTHERCited in: Complications, Comorbidities & Iatrogenic Risks
[205]
Delplanque M, Galicier L, Oziol E et al.. “AA Amyloidosis Secondary to Primary Immune Deficiency: About 40 Cases Including 2 New French Cases and a Systematic Literature Review.” The journal of allergy and clinical immunology. In practice (2020). PMID: 33007500 ↗
L4SR_OBSCited in: Prognosis & Natural History
[206]
Kuehn HS, Gloude NJ, Dimmock D et al.. “Abnormal SCID Newborn Screening and Spontaneous Recovery Associated with a Novel Haploinsufficiency IKZF1 Mutation.” Journal of clinical immunology (2021). PMID: 33855675 ↗
L4TRIAL_NONRANDOMCited in: Prognosis & Natural History, Prevention, Screening & Surveillance
[207]
van Leeuwen LPM, Van Coillie S, Prévot J et al.. “Long-term effects of COVID-19 in patients with primary immunodeficiency: An IPOPI worldwide survey.” The Journal of allergy and clinical immunology (2025). PMID: 40316182 ↗
L4OTHERCited in: Prognosis & Natural History
[208]
Verbsky JW, Hintermeyer MK, Simpson PM et al.. “Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency.” The Journal of allergy and clinical immunology (2020). PMID: 32745555 ↗
L4OTHERCited in: Prognosis & Natural History
[209]
da Silva SP, Resnick E, Lucas M et al.. “Lymphoid proliferations of indeterminate malignant potential arising in adults with common variable immunodeficiency disorders: unusual case studies and immunohistological review in the light of possible causative events.” Journal of clinical immunology (2011). PMID: 21744182 ↗
L4CASE_REPORTCited in: Prognosis & Natural History
[210]
Kuehn HS, Nunes-Santos CJ, Rosenzweig SD. “IKAROS-Associated Diseases in 2020: Genotypes, Phenotypes, and Outcomes in Primary Immune Deficiency/Inborn Errors of Immunity.” Journal of clinical immunology (2021). PMID: 33392855 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[211]
Caka C, Cimen O, Kahyaoğlu P et al.. “Selective IgM deficiency: Follow-up and outcome.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 33706406 ↗
L4OTHERCited in: Prognosis & Natural History, Special Populations & Pregnancy
[212]
Navale P, Zimmerman O, Wedner J et al.. “Gastrointestinal pathology in Good's syndrome, thinking beyond common variable immunodeficiency: a clinicopathological observation.” Virchows Archiv : an international journal of pathology (2025). PMID: 40140088 ↗
L4CASE_REPORTCited in: Prognosis & Natural History
[213]
Roosens W, Staels F, Van Loo S et al.. “Rituximab and improved nodular regenerative hyperplasia-associated non-cirrhotic liver disease in common variable immunodeficiency: a case report and literature study.” Frontiers in immunology (2023). PMID: 37795099 ↗
L4CASE_REPORTCited in: Prognosis & Natural History
[214]
Almejún MB, Campos BC, Patiño V et al.. “Noninfectious complications in patients with pediatric-onset common variable immunodeficiency correlated with defects in somatic hypermutation but not in class-switch recombination.” The Journal of allergy and clinical immunology (2016). PMID: 27713077 ↗
L4OTHERCited in: Special Populations & Pregnancy
[215]
Alsaati N, Penney C, Helbig I et al.. “A predictive model for identification of pediatric individuals with common variable immunodeficiency through electronic medical records.” The Journal of allergy and clinical immunology (2025). PMID: 40058414 ↗
L3OTHERCited in: Special Populations & Pregnancy
[216]
van de Ven AA, Compeer EB, Bloem AC et al.. “Defective calcium signaling and disrupted CD20-B-cell receptor dissociation in patients with common variable immunodeficiency disorders.” The Journal of allergy and clinical immunology (2011). PMID: 22130422 ↗
L3OTHERCited in: Special Populations & Pregnancy
[217]
Novice T, Kariminia A, Del Bel KL et al.. “A Germline Mutation in the C2 Domain of PLCγ2 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases.” Journal of clinical immunology (2019). PMID: 31853824 ↗
L4CASE_REPORTCited in: Special Populations & Pregnancy
[218]
Freer M, Bhatia R, Preece K et al.. “Dietary intakes and nutritional issues in inborn errors of immunity: a systematic review.” Frontiers in immunology (2024). PMID: 39399505 ↗
L2SR_OBSCited in: Special Populations & Pregnancy
[219]
Nijhof LN, van Brussel M, Pots EM et al.. “Severe Fatigue Is Common Among Pediatric Patients with Primary Immunodeficiency and Is Not Related to Disease Activity.” Journal of clinical immunology (2021). PMID: 33728554 ↗
L2OTHERCited in: Special Populations & Pregnancy
[220]
Sanchez LA, Maggadottir SM, Pantell MS et al.. “Two Sides of the Same Coin: Pediatric-Onset and Adult-Onset Common Variable Immune Deficiency.” Journal of clinical immunology (2017). PMID: 28755066 ↗
L2OTHERCited in: Special Populations & Pregnancy
[221]
Kinoshita H, Durkee-Shock J, Jensen-Wachspress M et al.. “Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.” Journal of clinical immunology (2021). PMID: 33983545 ↗
L3OTHERCited in: Special Populations & Pregnancy
[222]
Tanyildiz HG, Dincaslan H, Yavuz G et al.. “Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center.” Journal of clinical immunology (2016). PMID: 27492260 ↗
L4OTHERCited in: Special Populations & Pregnancy
[223]
Quinti I, Soresina A, Spadaro G et al.. “Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency.” Journal of clinical immunology (2007). PMID: 17510807 ↗
L2OTHERCited in: Special Populations & Pregnancy
[224]
Phuong LK, Cheung A, Agrawal R et al.. “Inborn Errors of Immunity in Children With Invasive Pneumococcal Disease: A Multicenter Prospective Study.” The Pediatric infectious disease journal (2023). PMID: 37463351 ↗
L2COHORTCited in: Special Populations & Pregnancy
[225]
Adin-Cinar S, Gelmez MY, Akdeniz N et al.. “Functions of NK and iNKT cells in pediatric and adult CVID, ataxia telangiectasia and agammaglobulinemia patients.” Immunology letters (2021). PMID: 34599947 ↗
L3TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[226]
Grześk E, Kołtan S, Dąbrowska A et al.. “Case report: Cellular therapy for hydroa vacciniforme-like lymphoproliferative disorder in pediatric common variable immunodeficiency with chronic active Epstein-Barr virus infection.” Frontiers in immunology (2022). PMID: 35990691 ↗
L4CASE_REPORTCited in: Special Populations & Pregnancy
[227]
Mokrane L, Tahiat A, Taguemount S et al.. “Improving screening for antibody deficiency using calculated globulin and serum protein electrophoresis.” Frontiers in immunology (2026). PMID: 41929515 ↗
L4OTHERCited in: Special Populations & Pregnancy, Prevention, Screening & Surveillance
[228]
Lucas M, Lee M, Lortan J et al.. “Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.” The Journal of allergy and clinical immunology (2010). PMID: 20471071 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[229]
Mayor PC, Eng KH, Singel KL et al.. “Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry.” The Journal of allergy and clinical immunology (2017). PMID: 28606585 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[230]
Green PHR, Paski S, Ko CW et al.. “AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review.” Gastroenterology (2022). PMID: 36137844 ↗
L1GUIDELINECited in: Prevention, Screening & Surveillance
[231]
Israeli S, Golden A, Atalig M et al.. “A Novel Point-of-Care Rapid Diagnostic Test for Screening Individuals for Antibody Deficiencies.” Journal of clinical immunology (2021). PMID: 34839430 ↗
L4OTHERCited in: Prevention, Screening & Surveillance
[232]
Kermode W, De Santis D, Truong L et al.. “A Novel Targeted Amplicon Next-Generation Sequencing Gene Panel for the Diagnosis of Common Variable Immunodeficiency Has a High Diagnostic Yield: Results from the Perth CVID Cohort Study.” The Journal of molecular diagnostics : JMD (2022). PMID: 35570134 ↗
L4COHORTCited in: Prevention, Screening & Surveillance
[233]
Nassereddin AT, Zayed Y, King RB et al.. “A 28-Year-Old Woman With Nail Discoloration, Recurrent Bronchitis, and Left-Sided Facial Swelling.” Chest (2023). PMID: 37945195 ↗
L4CASE_REPORTCited in: Prevention, Screening & Surveillance
[234]
Camacho-Ordonez N, Hirsch A, Campos L et al.. “Do CVID patients on SCIG have more autoimmune (thrombo)cytopenic events than CVID patients on IVIG?” Frontiers in immunology (2025). PMID: 41394859 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[235]
Alba-Cano T, Alonso R, Balastegui-Martín H et al.. “Impact of CMV latency on T-cell responses to COVID-19 vaccination among predominantly antibody-deficient patients.” Frontiers in immunology (2025). PMID: 41098714 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[236]
Chandrasekaran P, Krausz M, Han Y et al.. “The intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency.” Microbiome (2025). PMID: 39934899 ↗
L4Cited in: Pathophysiology & Immune Mechanism
[237]
Ortiz Requena D, Montgomery EA, Ronquillo NR et al.. “Multiple Myeloma and Mimicry: Gastrointestinal Tract Histologic Findings in Patients Following Chimeric Antigen Receptor T-cell Therapy and Anti-CD38 Monoclonal Antibodies.” Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (2026). PMID: 41864428 ↗
L4Cited in: Pathophysiology & Immune Mechanism
[238]
Tahiat A, Touri S, Saad-Djaballah A et al.. “Mapping the landscape of autoimmunity and autoinflammation in inborn errors of immunity: broad distribution with distinct clustering patterns.” Frontiers in immunology (2025). PMID: 41394846 ↗
L3bCited in: Pathophysiology & Immune Mechanism
[239]
Bez P, Santangeli E, Goldacker S et al.. “Expansion of CD57+ CD8 T cells in common variable immunodeficiency with hepatopathy and CMV infection.” Frontiers in immunology (2025). PMID: 40496855 ↗
L3bCited in: Pathophysiology & Immune Mechanism
[240]
Emmaneel A, Neirinck J, Torres-Valle A et al.. “PIDgeon: An Explainable AI Model for Improved Flow Cytometry-Based Screening of Lymphoid Primary Immunodeficiencies.” Clinical chemistry (2026). PMID: 41605242 ↗
L3bCited in: Pathophysiology & Immune Mechanism
[241]
Lopes da Silva VG, Schmitz GJH, Sullivan KE et al.. “Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.” Frontiers in immunology (2025). PMID: 40114918 ↗
L4Cited in: Pathophysiology & Immune Mechanism
[242]
Felixberger PT, Andrieux G, Maul-Pavicic A et al.. “CD21low B cells reveal a unique glycosylation pattern with hypersialylation and hyperfucosylation.” Frontiers in immunology (2025). PMID: 40013136 ↗
L3bCited in: Pathophysiology & Immune Mechanism
[243]
Li M, Wang Q, Chen Y et al.. “Relieving the discrimination dilemma of adult autoimmune enteropathy and common variable immunodeficiency disease: two rare causes of chronic diarrhea and small intestinal villous atrophy.” Clinical rheumatology (2025). PMID: 40622608 ↗
L3bCited in: Pathophysiology & Immune Mechanism
[244]
Jogdand A, Gilbert KM, Hong JS et al.. “Utility of serum cytokine testing to differentiate complicated common variable immunodeficiency in resource limited settings.” The journal of allergy and clinical immunology. Global (2025). PMID: 40497017 ↗
L3bCited in: Pathophysiology & Immune Mechanism
[245]
Cousin V, Graumann A, Geiger V et al.. “Elevated IL-10 is Linked With the Expansion of T-bethighCD21low B Cells in Patients With Common Variable Immunodeficiency.” Journal of clinical immunology (2026). PMID: 42603226 ↗
L5Cited in: Pathophysiology & Immune Mechanism
[246]
Moriya K, Kamiyama Y, Ogino R et al.. “Clinical and immunological characterization of NFKB1 haploinsufficiency in Japan.” Frontiers in immunology (2026). PMID: 42488646 ↗
L5Cited in: Pathophysiology & Immune Mechanism
[247]
Moral Moral P, Cabanero-Navalon MD, López-León PT et al.. “Infectious outcomes of a standardized subcutaneous immunoglobulin dose reduction strategy in primary immune deficiencies amid global shortage.” Frontiers in immunology (2025). PMID: 39902048 ↗
L4Cited in: Epidemiology, Etiology & Risk Factors
[248]
Korkmaz P, Toprak İD, Hormet Igde M et al.. “Tuberculosis screening in adult patients with inborn errors of immunity: a single-center cohort study.” Frontiers in immunology (2026). PMID: 42568392 ↗
L4Cited in: Epidemiology, Etiology & Risk Factors
[249]
Dogru Y, Atschekzei F, Dogru D et al.. “Clinical and immunological differentiation of isolated IgG and combined IgG & IgM deficiencies from common variable immunodeficiency.” Frontiers in immunology (2026). PMID: 41869311 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors
[250]
Mechernene B, Lehours P, Rivière E et al.. “Stool Screening for Campylobacter Species in Hypogammaglobulinemic Patients Receiving Immunoglobulin Therapy.” Journal of clinical immunology (2025). PMID: 41099909 ↗
L4Cited in: Epidemiology, Etiology & Risk Factors
[251]
Martínez Mercader S, Garcia-Bustos V, Moral Moral P et al.. “Exploring Multidimensional Risk Factors Associated with Local Adverse Reactions to Subcutaneous Immunoglobulin Therapy: Insights from a Nationwide Multicenter Study.” Biomedicines (2025). PMID: 40868242 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors
[252]
Elamine A, Benhsaien I, Ailal F et al.. “Autoimmune manifestations in children with inborn errors of immunity in Morocco: A study from the national registry.” Journal of translational autoimmunity (2025). PMID: 40678816 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors
[253]
Ameratunga R, Byrnes CA, Jordan A et al.. “Common Variable Immune Deficiency Disorders (CVID) in the Indigenous Māori of Aotearoa (New Zealand) Are Associated With a High Prevalence of Bronchiectasis and Complete IgA Deficiency.” Scandinavian journal of immunology (2025). PMID: 41267378 ↗
L4Cited in: Epidemiology, Etiology & Risk Factors
[254]
Moral Moral P, Garcia-Bustos V, Balastegui-Martin H et al.. “Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study.” Frontiers in immunology (2025). PMID: 40771807 ↗
L3bCited in: Clinical Presentation
[255]
Allaoui A, Moundir A, Benhsaien I et al.. “Clinical, immunological, and genetic landscape of common variable immunodeficiency in Morocco: a nationwide multicenter study.” Frontiers in immunology (2025). PMID: 40703516 ↗
L3bCited in: Clinical Presentation
[256]
Gerek ME, Colkesen F, Onalan T et al.. “Comparative analysis of demographic and clinical features in common variable immunodeficiency and selective immunoglobulin G deficiency.” Allergy and asthma proceedings (2025). PMID: 41152686 ↗
L4Cited in: Clinical Presentation
[257]
Danieli MG, Claudi I, Auria S et al.. “Allergic Diseases in Common Variable Immunodeficiency: A Prospective Cross-Sectional Study on Prevalence and Allergy Biomarkers of Clinical Phenotypes.” Scandinavian journal of immunology (2026). PMID: 41845886 ↗
L3bCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[258]
Lawrence MG, Kim VHD, Orange JS et al.. “Shared Decision-Making and Health-Related Quality of Life in the Diagnosis and Management of Patients With Inborn Errors of Immunity.” The journal of allergy and clinical immunology. In practice (2026). PMID: 42447994 ↗
L5Cited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[259]
Milito C, Firinu D, Bez P et al.. “A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes.” Frontiers in immunology (2023). PMID: 36845159 ↗
L2bCited in: Severity, Grading & Risk Stratification
[260]
Pulvirenti F, Giufrè M, Pentimalli TM et al.. “Oropharyngeal microbial ecosystem perturbations influence the risk for acute respiratory infections in common variable immunodeficiency.” Frontiers in immunology (2024). PMID: 38873612 ↗
L3bCited in: Severity, Grading & Risk Stratification
[261]
Daza-Cajigal V, Segura-Guerrero M, López-Cueto M et al.. “Clinical manifestations and approach to the management of patients with common variable immunodeficiency and liver disease.” Frontiers in immunology (2023). PMID: 37342345 ↗
L4Cited in: Severity, Grading & Risk Stratification
[262]
Pendse AA, Maule JG, Neff JL et al.. “Plasma cells are essentially absent in the luminal gastrointestinal tract of patients with "complete" 22q11.2 deletion syndrome (DiGeorge syndrome).” Human pathology (2021). PMID: 34391747 ↗
L3bCited in: Severity, Grading & Risk Stratification
[263]
Makary CA, Behnke J, Peppers B et al.. “Outcome of Immunoglobulin Replacement Therapy in Adults With Rhinosinusitis.” The Laryngoscope (2021). PMID: 34146351 ↗
L4Cited in: Severity, Grading & Risk Stratification
[264]
Bagkou Dimakou D, Peters NE, Burns SO et al.. “Serum sBCMA in primary and secondary antibody deficiency.” Clinical and experimental immunology (2025). PMID: 41017320 ↗
L3bCited in: Severity, Grading & Risk Stratification
[265]
Guerra-Galán T, Palacios-Ortega M, Jiménez-Huete A et al.. “An Exploratory Approach of Clinically Useful Biomarkers of Cvid by Logistic Regression.” Journal of clinical immunology (2024). PMID: 38847936 ↗
L3bCited in: Severity, Grading & Risk Stratification
[266]
Więsik-Szewczyk E, Rutkowska E, Kwiecień I et al.. “Patients with Common Variable Immunodeficiency Complicated by Autoimmune Phenomena Have Lymphopenia and Reduced Treg, Th17, and NK Cells.” Journal of clinical medicine (2021). PMID: 34362140 ↗
L4Cited in: Severity, Grading & Risk Stratification
[267]
van Leeuwen LPM, Grobben M, GeurtsvanKessel CH et al.. “Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.” Frontiers in immunology (2024). PMID: 38698851 ↗
L4Cited in: Acute Management & Anaphylaxis Pathway
[268]
Lin FJ, Doss AMA, Davis-Adams HG et al.. “SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients.” Frontiers in immunology (2022). PMID: 36618402 ↗
L2bCited in: Acute Management & Anaphylaxis Pathway
[269]
Svačina MKR, Meißner A, Schweitzer F et al.. “Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.” European journal of neurology (2023). PMID: 37789648 ↗
L4Cited in: Acute Management & Anaphylaxis Pathway
[270]
Cabañero-Navalon MD, Garcia-Bustos V, Nuñez-Beltran M et al.. “Current clinical spectrum of common variable immunodeficiency in Spain: The multicentric nationwide GTEM-SEMI-CVID registry.” Frontiers in immunology (2022). PMID: 36389743 ↗
L3bCited in: Acute Management & Anaphylaxis Pathway
[271]
La Civita E, Zannella C, Brusa S et al.. “BNT162b2 Elicited an Efficient Cell-Mediated Response against SARS-CoV-2 in Kidney Transplant Recipients and Common Variable Immunodeficiency Patients.” Viruses (2023). PMID: 37632002 ↗
L3bCited in: Acute Management & Anaphylaxis Pathway
[272]
Goda V, Kriván G, Kulcsár A et al.. “Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency.” Frontiers in immunology (2022). PMID: 35784359 ↗
L3bCited in: Acute Management & Anaphylaxis Pathway
[273]
Sauerwein KMT, Geier CB, Stemberger RF et al.. “Antigen-Specific CD4+ T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination.” Frontiers in immunology (2022). PMID: 35237272 ↗
L3bCited in: Acute Management & Anaphylaxis Pathway
[274]
Guevara-Hoyer K, Saz-Leal P, Diez-Rivero CM et al.. “Trained Immunity Based-Vaccines as a Prophylactic Strategy in Common Variable Immunodeficiency. A Proof of Concept Study.” Biomedicines (2020). PMID: 32660100 ↗
L3bCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[275]
Quartuccio L, De Marchi G, Longhino S et al.. “Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine.” Frontiers in immunology (2021). PMID: 34322134 ↗
L5Cited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[276]
Cunningham-Rundles C. “How I treat common variable immune deficiency.” Blood (2010). PMID: 20332369 ↗
L5Cited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[277]
Antachopoulos C. “Invasive fungal infections in congenital immunodeficiencies.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2010). PMID: 20840542 ↗
L5Cited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[278]
Danieli MG, Murdaca G, Mezzanotte C et al.. “Polyautoimmunity Reflecting Immune Dysregulation in Common Variable Immunodeficiency.” Biomedicines (2025). PMID: 40149529 ↗
L4Cited in: Complications, Comorbidities & Iatrogenic Risks
[279]
Martínez Mercader S, Garcia-Bustos V, Moral Moral P et al.. “Patient-centered outcomes with subcutaneous immunoglobulin use for infection control in primary and secondary immunodeficiencies: data of a GEIE Spanish Registry.” Frontiers in immunology (2025). PMID: 40028320 ↗
L3bCited in: Complications, Comorbidities & Iatrogenic Risks
[280]
Marri L, Contini P, Ivaldi F et al.. “Evaluation of Frequency of CMV Replication and Disease Complications Reveals New Cellular Defects and a Time Dependent Pattern in CVID Patients.” Journal of clinical immunology (2024). PMID: 38847943 ↗
L3bCited in: Prognosis & Natural History
[281]
Sadi Aykan F, Akın Saygın D, Çölkesen F et al.. “Brain Volume Alterations and Cognitive Functions in Patients with Common Variable Immunodeficiency: Evaluating the Impact of Autoimmunity.” Journal of clinical medicine (2026). PMID: 41598442 ↗
L3bCited in: Prognosis & Natural History
[282]
Cabañero-Navalon MD, Garcia-Bustos V, Balastegui-Martin H et al.. “The impact of immune dysregulation on the risk of malignancy in common variable immunodeficiency: insights from a multicenter study.” Frontiers in immunology (2024). PMID: 39478863 ↗
L3bCited in: Prognosis & Natural History
[283]
Correa-Jimenez O, Restrepo-Gualteros S, Nino G et al.. “Respiratory Comorbidities Associated with Bronchiectasis in Patients with Common Variable Immunodeficiency in the USIDNET Registry.” Journal of clinical immunology (2023). PMID: 37932514 ↗
L3bCited in: Prognosis & Natural History
[284]
Ciccarese F, Piva N, Carpano M et al.. “CT Features of Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD): The "Kebab Sign" as a Marker to Support Differential Diagnosis.” Diagnostics (Basel, Switzerland) (2026). PMID: 42196862 ↗
L4Cited in: Prognosis & Natural History
[285]
King AL, Johnson EF, Alavi A et al.. “The Spectrum of Cutaneous Granulomatous Inflammation and Detection of Rubella Virus in Skin Biopsies of Patients With Common Variable Immune Deficiency.” Journal of cutaneous pathology (2024). PMID: 39588762 ↗
L4Cited in: Prognosis & Natural History
[286]
Pulvirenti F, Villa A, D'Ambrosi M et al.. “Changes in health-related quality of life in common variable immunodeficiency: an eight-year journey, including the COVID-19 pandemic.” Expert review of clinical immunology (2024). PMID: 38994591 ↗
L3bCited in: Prognosis & Natural History
[287]
Tessarin G, Baronio M, Gazzurelli L et al.. “Rituximab Monotherapy Is Effective as First-Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in CVID Patients.” Journal of clinical immunology (2023). PMID: 37755605 ↗
L4Cited in: Prognosis & Natural History
[288]
Bintalib HM, Raya RP, Alluhibi R et al.. “Utility of the 6-minute walk test and health-related quality of life questionnaires in granulomatous and lymphocytic interstitial lung disease.” Multidisciplinary respiratory medicine (2026). PMID: 42083912 ↗
L4Cited in: Prognosis & Natural History
[289]
Teräsjärvi J, Kainulainen L, Peltola V et al.. “Genetic polymorphisms of TLR1, TLR2, TLR3 and TLR4 in patients with recurrent or severe infections.” International journal of immunogenetics (2024). PMID: 38706134 ↗
L4Cited in: Prognosis & Natural History
[290]
Milito C, Pulvirenti F, Garzi G et al.. “Decline of gastric cancer mortality in common variable immunodeficiency in the years 2018-2022.” Frontiers in immunology (2023). PMID: 37868983 ↗
L4Cited in: Prevention, Screening & Surveillance
[291]
Bruns L, Panagiota V, von Hardenberg S et al.. “Common Variable Immunodeficiency-Associated Cancers: The Role of Clinical Phenotypes, Immunological and Genetic Factors.” Frontiers in immunology (2022). PMID: 35250968 ↗
L3bCited in: Prevention, Screening & Surveillance
[292]
Krausz M, Sogkas G, Uhlmann A et al.. “ABACHAI - Safety and efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency, a phase II clinical trial.” The Journal of allergy and clinical immunology (2026). PMID: 42763023 ↗
L2bCited in: Epidemiology, Etiology & Risk Factors
[293]
Yigitdol I, Colkesen F, Gerek ME et al.. “Prevalence, associated clinical factors, and genetic characteristics of endocrinopathies in common variable immunodeficiency: a retrospective study of 95 adult patients from a single tertiary care center.” Frontiers in immunology (2026). PMID: 42707139 ↗
L4Cited in: Epidemiology, Etiology & Risk Factors
[294]
Patel C, Cheng J, Zhou J et al.. “Characterization of Histologic Spectrum and T-Cell Clonality in Immune Effector Cell-Associated Enteritis.” Human pathology (2026). PMID: 42763062 ↗
L4Cited in: Severity, Grading & Risk Stratification
[295]
Cabanero-Navalon MD, Carda-Diéguez M, Mira A et al.. “Multiniche mycobiome profiling identifies distinctive fungal dysbiosis in common variable immunodeficiency.” Frontiers in immunology (2026). PMID: 42245662 ↗
L3bCited in: Severity, Grading & Risk Stratification
[296]
Walsh JE, Gurrola JG, Graham SM et al.. “Immunoglobulin replacement therapy reduces chronic rhinosinusitis in patients with antibody deficiency.” International forum of allergy & rhinology (2016). PMID: 27552393 ↗
L5Cited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[297]
Petrusenko Y, Savin T, Sedykh A et al.. “Genetic Heterogeneity of Inborn Errors of Immunity Revealed by Whole-Genome Sequencing: Insights from a Russian Patient Cohort.” International journal of molecular sciences (2026). PMID: 42737820 ↗
L4Cited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[298]
Demir S, Kahveci N, Gelmez MY et al.. “Mucosal regulatory and effector T-cell imbalance in CVID-associated enteropathy.” Frontiers in immunology (2026). PMID: 42756343 ↗
L4Cited in: Complications, Comorbidities & Iatrogenic Risks
[299]
Syed MN, Kutac C, Miller JM et al.. “Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).” Journal of clinical immunology (2022). PMID: 35779201 ↗
L4Cited in: Prevention, Screening & Surveillance